antiatherosclerotic agent - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	antiatherosclerotic agent	go back to main search page
Accession:	CHEBI:145947	browse the term
Definition:	A cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent.
Synonyms:	related_synonym:	anti-atherosclerotic agent; anti-atherosclerotic agents; anti-atherosclerotic drug; anti-atherosclerotic drugs; antiatherosclerotic agents; antiatherosclerotic drug; antiatherosclerotic drugs

show annotations for term's descendants Sort by:
Rat (1694) Mouse (1945) Human (1706) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (5) Green Monkey (0) Naked Mole-rat (0) All
Genes (1706)

baicalin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase (Yt blood group)

multiple interactions
increases expression

baicalin results in increased expression of and results in increased activity of ACHE protein
baicalin results in increased expression of ACHE mRNA

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

aryl hydrocarbon receptor

increases activity

baicalin results in increased activity of AHR protein

PMID:17869316 PMID:26204831

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

allograft inflammatory factor 1

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]

NCBI chr 6:31,615,234...31,617,015
Ensembl chr 6:31,615,217...31,617,021

G

albumin

multiple interactions

baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of ALB protein]

NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482

G

arachidonate 5-lipoxygenase

multiple interactions

baicalin inhibits the reaction [Hydrogen Peroxide affects the localization of and results in increased activity of ALOX5 protein]

NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119

G

angiopoietin 1

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of ANGPT1 mRNA]

NCBI chr 8:107,249,482...107,497,918
Ensembl chr 8:107,249,482...107,498,055

G

activating transcription factor 2

multiple interactions

baicalin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of ATF2 protein]

NCBI chr 2:175,072,259...175,168,203
Ensembl chr 2:175,072,250...175,168,382

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

baicalin results in increased expression of BAX protein
baicalin affects the reaction [Rotenone results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Rotenone results in increased expression of BAX protein]
baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX protein]
baicalin inhibits the reaction [Rotenone affects the expression of BAX protein]

PMID:21457722 PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 More...

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

BCL2 apoptosis regulator

multiple interactions
decreases expression

baicalin inhibits the reaction [Rotenone affects the expression of BCL2 protein]
baicalin affects the reaction [Rotenone results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Rotenone results in decreased expression of BCL2 protein]
baicalin results in decreased expression of BCL2 protein
baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein]

PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

caspase 1

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]

NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250

G

caspase 3

multiple interactions

baicalin inhibits the reaction [Rotenone affects the expression of CASP3 protein]
baicalin affects the reaction [Rotenone results in decreased activity of CASP3 protein]
baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; baicalin inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]

PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

catalase

multiple interactions

baicalin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]

PMID:34333357 PMID:35088608

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cyclin A2

decreases expression

baicalin results in decreased expression of CCNA2 protein

NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883

G

cyclin D1

increases expression
decreases expression
multiple interactions

baicalin results in increased expression of CCND1 mRNA
baicalin results in decreased expression of CCND1 protein
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA]

PMID:19160421 PMID:21457722

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

collagen type I alpha 2 chain

multiple interactions

baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA]

NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions
increases expression

3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 protein]; baicalin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
baicalin results in increased expression of CYP1A1 mRNA; baicalin results in increased expression of CYP1A1 protein

PMID:18451504 PMID:26204831

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

multiple interactions
increases expression

3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 protein]
resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 protein]
baicalin results in increased expression of CYP1A2 mRNA; baicalin results in increased expression of CYP1A2 protein

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

epidermal growth factor

multiple interactions

baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]

NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766

G

epidermal growth factor receptor

multiple interactions

baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]

NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628

G

ETS transcription factor ELK1

multiple interactions

baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]

NCBI chr X:47,635,520...47,650,604
Ensembl chr X:47,635,520...47,650,604

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

baicalin inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein]

NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819

G

forkhead box A2

decreases expression

baicalin results in decreased expression of FOXA2 mRNA; baicalin results in decreased expression of FOXA2 protein

NCBI chr20:22,580,998...22,585,490
Ensembl chr20:22,580,998...22,585,455

G

glutamic-oxaloacetic transaminase 1

multiple interactions

baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GOT1 protein]

NCBI chr10:99,396,870...99,430,624
Ensembl chr10:99,396,870...99,430,624

G

glutamic--pyruvic transaminase

multiple interactions

baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein]
baicalin inhibits the reaction [Arsenic Trioxide results in increased activity of GPT protein]

PMID:15645217 PMID:35088608

NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174

G

hes family bHLH transcription factor 1

increases expression
multiple interactions

baicalin results in increased expression of HES1 mRNA
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]

NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732

G

hes related family bHLH transcription factor with YRPW motif 1

increases expression
multiple interactions

baicalin results in increased expression of HEY1 mRNA
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA]

NCBI chr 8:79,764,010...79,767,767
Ensembl chr 8:79,762,371...79,767,857

G

hes related family bHLH transcription factor with YRPW motif 2

multiple interactions
increases expression

N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]

NCBI chr 6:125,749,632...125,761,269
Ensembl chr 6:125,747,664...125,761,269

G

heme oxygenase 1

multiple interactions
increases expression

[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HMOX1 protein]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]
baicalin results in increased expression of HMOX1 mRNA; baicalin results in increased expression of HMOX1 protein

PMID:16824337 PMID:18187930 PMID:38016618

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

HNF1 homeobox A

decreases expression
multiple interactions

baicalin results in decreased expression of HNF1A mRNA; baicalin results in decreased expression of HNF1A protein
baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF1A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein]

NCBI chr12:120,978,543...121,002,512
Ensembl chr12:120,978,543...121,002,512

G

hepatocyte nuclear factor 4 alpha

decreases expression
multiple interactions

baicalin results in decreased expression of HNF4A protein
baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein]; HNF4A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens]
baicalin results in decreased expression of HNF4A mRNA; baicalin results in decreased expression of HNF4A protein

NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,699...44,432,845

G

heat shock protein family B (small) member 1

multiple interactions

baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of HSPB1 protein]

NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,305,813

G

interleukin 1 beta

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL1B protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]
baicalin inhibits the reaction [Rotenone results in increased expression of IL1B protein]

PMID:29031535 PMID:35088608 PMID:36446982 PMID:38016618

NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816

G

interleukin 6

decreases expression
multiple interactions

baicalin results in decreased expression of IL6 mRNA; baicalin results in decreased expression of IL6 protein
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL6 protein]

PMID:22019745 PMID:29031535 PMID:34333357 PMID:35088608 PMID:38016618

NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002

G

INS-IGF2 readthrough

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

integrin subunit alpha 4

multiple interactions

baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]; baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein]

NCBI chr 2:181,457,205...181,538,940
Ensembl chr 2:181,457,202...181,538,940

G

Janus kinase 2

multiple interactions

baicalin promotes the reaction [Arsenic Trioxide results in increased phosphorylation of JAK2 protein]

NCBI chr 9:4,984,390...5,129,948
Ensembl chr 9:4,984,390...5,129,948

G

kinase insert domain receptor

multiple interactions

baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]

NCBI chr 4:55,078,481...55,125,595
Ensembl chr 4:55,078,481...55,125,595

G

kelch like ECH associated protein 1

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein]

NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558

G

mitogen-activated protein kinase 1

multiple interactions

baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 3

multiple interactions

baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]

NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506

G

MYD88 innate immune signal transduction adaptor

decreases expression

baicalin results in decreased expression of MYD88 protein

NCBI chr 3:38,138,661...38,143,022
Ensembl chr 3:38,138,552...38,143,024

G

NFE2 like bZIP transcription factor 2

multiple interactions

[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

NFKB inhibitor alpha

increases expression

baicalin results in increased expression of NFKBIA protein

NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749

G

NLR family pyrin domain containing 3

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]

PMID:29031535 PMID:38016618

NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108

G

nitric oxide synthase 2

multiple interactions
decreases expression

baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]
baicalin results in decreased expression of NOS2 mRNA; baicalin results in decreased expression of NOS2 protein
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; mifobate inhibits the reaction [baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]

PMID:18187930 PMID:22019745 PMID:24312512

NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529

G

notch receptor 1

increases activity
increases expression

baicalin results in increased activity of NOTCH1 protein
baicalin results in increased expression of NOTCH1 mRNA

NCBI chr 9:136,494,433...136,546,048
Ensembl chr 9:136,494,433...136,546,048

G

nuclear receptor subfamily 1 group H member 3

increases expression

Baicalin increases expression of NR1H3 mRNA and protein in foam cells

RGD

NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033

G

pyruvate kinase M1/2

increases activity

baicalin results in increased activity of PKM protein

NCBI chr15:72,199,029...72,231,591
Ensembl chr15:72,199,029...72,231,819

G

peroxisome proliferator activated receptor gamma

multiple interactions

baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of and results in decreased activity of PPARG protein]

NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356

G

proline rich membrane anchor 1

increases expression

baicalin results in increased expression of PRIMA1 mRNA

NCBI chr14:93,718,298...93,788,994
Ensembl chr14:93,718,298...93,788,485

G

prostaglandin-endoperoxide synthase 2

decreases expression

baicalin results in decreased expression of PTGS2 mRNA; baicalin results in decreased expression of PTGS2 protein

NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922

G

PYD and CARD domain containing

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]

NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

baicalin affects the localization of and results in decreased expression of RELA protein
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of and results in increased phosphorylation of RELA protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]

PMID:22019745 PMID:34333357 PMID:38016618

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

synuclein alpha

multiple interactions

[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; [baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]]

NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315

G

signal transducer and activator of transcription 3

multiple interactions

baicalin promotes the reaction [Arsenic Trioxide results in increased phosphorylation of STAT3 protein]

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

TEK receptor tyrosine kinase

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of TEK mRNA]

NCBI chr 9:27,109,225...27,230,174
Ensembl chr 9:27,109,141...27,230,174

G

transcription factor A, mitochondrial

multiple interactions
decreases expression

baicalin inhibits the reaction [Rotenone results in decreased expression of TFAM mRNA]
baicalin results in decreased expression of TFAM mRNA

NCBI chr10:58,385,410...58,399,220
Ensembl chr10:58,385,345...58,399,220

G

transforming growth factor beta 1

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of TGFB1 mRNA]; baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA]

PMID:19474275 PMID:34414639

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

tyrosine hydroxylase

multiple interactions

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TH protein]

NCBI chr11:2,163,929...2,171,815
Ensembl chr11:2,163,929...2,171,815

G

toll like receptor 4

decreases expression
multiple interactions

baicalin results in decreased expression of TLR4 protein
baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TLR4 protein]
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]

PMID:22019745 PMID:24312512 PMID:34333357

NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735

G

tumor necrosis factor

multiple interactions
decreases expression

baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]
baicalin results in decreased expression of TNF mRNA; baicalin results in decreased expression of TNF protein
baicalin inhibits the reaction [Paraquat results in increased expression of TNF protein]

PMID:16824337 PMID:18187930 PMID:22019745 PMID:34333357 PMID:35088608 More...

NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336

G

tumor protein p53

increases expression

baicalin results in increased expression of TP53 protein

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546

G

thioredoxin interacting protein

multiple interactions

baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]; dorsomorphin inhibits the reaction [baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]]

NCBI chr 1:145,992,435...145,996,579
Ensembl chr 1:145,992,435...145,996,579

G

ubiquitin specific peptidase 27 X-linked

multiple interactions

baicalin inhibits the reaction [Streptozocin results in increased expression of USP27X protein]

NCBI chr X:49,879,484...49,882,558
Ensembl chr X:49,879,484...49,882,558

G

vascular endothelial growth factor A

multiple interactions

baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein]

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vascular endothelial growth factor C

multiple interactions

baicalin inhibits the reaction [Streptozocin results in decreased expression of VEGFC mRNA]

NCBI chr 4:176,683,538...176,792,922
Ensembl chr 4:176,683,538...176,792,922

G

xanthine dehydrogenase

multiple interactions

baicalin inhibits the reaction [[Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein]

NCBI chr 2:31,334,321...31,414,742
Ensembl chr 2:31,334,321...31,414,742

dextran sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA

NCBI chr16:8,674,617...8,784,570
Ensembl chr16:8,674,596...8,784,575

G

ATP binding cassette subfamily A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA

NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155

G

ATP binding cassette subfamily A member 17, pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA17 mRNA

NCBI chr16:2,340,922...2,426,699
Ensembl chr16:2,361,144...2,425,685
Ensembl chr16:2,361,144...2,425,685

G

ATP binding cassette subfamily B member 1

multiple interactions
decreases expression
increases response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dextran Sulfate results in decreased expression of ABCB1A mRNA
ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate

PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily B member 11

decreases expression

Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein

NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324

G

ATP binding cassette subfamily B member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA

NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435

G

ATP binding cassette subfamily B member 6 (LAN blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA

NCBI chr 2:219,209,772...219,218,958
Ensembl chr 2:219,209,772...219,218,994

G

ATP binding cassette subfamily C member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA

NCBI chr 6:43,427,541...43,451,994
Ensembl chr 6:43,427,366...43,450,430

G

ATP binding cassette subfamily C member 2

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein
ABCC2 protein affects the susceptibility to Dextran Sulfate
ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:30701287

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily C member 3

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein
ABCC3 protein affects the susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:29950665 PMID:30701287

NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253

G

ATP binding cassette subfamily C member 4 (PEL blood group)

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA
Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein

PMID:26271895 PMID:27580383 PMID:29950665

NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475

G

ATP binding cassette subfamily C member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA

NCBI chr 3:183,919,934...184,017,884
Ensembl chr 3:183,919,934...184,017,939

G

ATP binding cassette subfamily C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA

NCBI chr16:16,149,565...16,223,494
Ensembl chr16:16,149,565...16,223,522

G

ATP binding cassette subfamily C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA

NCBI chr12:21,797,389...21,941,426
Ensembl chr12:21,797,389...21,942,543

G

ATP binding cassette subfamily F member 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein]

NCBI chr 7:151,211,484...151,227,205
Ensembl chr 7:151,211,484...151,227,205

G

ATP binding cassette subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA

NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,304,389

G

ATP binding cassette subfamily G member 2 (JR blood group)

multiple interactions
decreases expression
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]
Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein
ABCG2 protein affects the susceptibility to Dextran Sulfate

PMID:29950665 PMID:30701287 PMID:38423481

NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628

G

abl interactor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein]

NCBI chr10:26,746,596...26,860,958
Ensembl chr10:26,746,593...26,861,087

G

acetyl-CoA acyltransferase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA

NCBI chr 3:38,122,715...38,137,127
Ensembl chr 3:38,103,129...38,137,242

G

acetyl-CoA acyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA

NCBI chr18:49,782,164...49,813,533
Ensembl chr18:49,782,164...49,813,953

G

acetyl-CoA carboxylase alpha

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ACACA protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein]

NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836

G

acyl-CoA dehydrogenase short chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA

NCBI chr12:120,725,826...120,740,008
Ensembl chr12:120,725,774...120,740,008

G

acyl-CoA dehydrogenase short/branched chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA

NCBI chr10:123,009,006...123,058,290
Ensembl chr10:123,008,979...123,058,290

G

angiotensin I converting enzyme

multiple interactions
increases abundance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA
dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space

CTD
RGD

PMID:29950665 PMID:26401072

NCBI chr17:63,477,061...63,498,373
Ensembl chr17:63,477,061...63,498,380

G

acetylcholinesterase (Yt blood group)

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA
Dextran Sulfate results in decreased activity of ACHE protein

PMID:29950665 PMID:31226429 PMID:31807802

NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974

G

atypical chemokine receptor 1 (Duffy blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA

NCBI chr 1:159,204,875...159,206,500
Ensembl chr 1:159,204,875...159,206,500

G

atypical chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA

NCBI chr 3:42,809,445...42,867,286
Ensembl chr 3:42,804,752...42,887,974

G

atypical chemokine receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA

NCBI chr 2:236,537,122...236,582,354
Ensembl chr 2:236,567,787...236,582,354

G

atypical chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA

NCBI chr 3:132,597,270...132,602,644
Ensembl chr 3:132,597,270...132,618,967

G

acyl-CoA synthetase bubblegum family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA

NCBI chr19:6,135,633...6,193,091
Ensembl chr19:6,135,247...6,193,094

G

acyl-CoA synthetase medium chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA

NCBI chr16:20,623,235...20,697,680
Ensembl chr16:20,623,235...20,698,890

G

acyl-CoA synthetase medium chain family member 3

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein]

NCBI chr16:20,674,405...20,797,581
Ensembl chr16:20,610,243...20,797,581

G

acyl-CoA synthetase short chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA

NCBI chr20:25,006,237...25,058,139
Ensembl chr20:25,006,230...25,058,980

G

acyl-CoA synthetase short chain family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA

NCBI chr20:34,874,989...34,927,959
Ensembl chr20:34,872,146...34,927,962

G

actin like 6A

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein]

NCBI chr 3:179,562,926...179,588,407
Ensembl chr 3:179,562,886...179,588,407

G

actinin alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA

NCBI chr14:68,874,128...68,979,302
Ensembl chr14:68,874,123...68,979,440

G

actinin alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA

NCBI chr 1:236,686,499...236,764,631
Ensembl chr 1:236,664,141...236,764,631

G

actin related protein 2

decreases expression

Dextran Sulfate results in decreased expression of ACTR2 protein

NCBI chr 2:65,227,831...65,271,253
Ensembl chr 2:65,227,788...65,271,253

G

actin related protein 3

decreases expression

Dextran Sulfate results in decreased expression of ACTR3 protein

NCBI chr 2:113,889,934...113,962,596
Ensembl chr 2:113,890,063...113,962,596

G

activin A receptor type 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA

NCBI chr 2:157,736,446...157,876,330
Ensembl chr 2:157,736,251...157,876,330

G

aminoacylase 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein

NCBI chr 3:51,983,535...51,989,197
Ensembl chr 3:51,983,340...51,989,197

G

adenosine deaminase

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein]

NCBI chr20:44,619,522...44,651,699
Ensembl chr20:44,584,896...44,652,252

G

ADAM metallopeptidase domain 17

multiple interactions
increases expression
affects response to substance

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]
ADAM17 protein affects the susceptibility to Dextran Sulfate

NCBI chr 2:9,488,486...9,555,830
Ensembl chr 2:9,488,486...9,556,732

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA

NCBI chr21:26,835,755...26,845,409
Ensembl chr21:26,835,755...26,845,409

G

ADAM metallopeptidase with thrombospondin type 1 motif 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA

NCBI chr10:70,672,506...70,762,441
Ensembl chr10:70,672,506...70,762,441

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA

NCBI chr 5:179,110,853...179,345,461
Ensembl chr 5:179,110,853...179,345,461

G

ADAM metallopeptidase with thrombospondin type 1 motif 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA

NCBI chr 1:161,184,302...161,199,054
Ensembl chr 1:161,184,302...161,199,054

G

ADAM metallopeptidase with thrombospondin type 1 motif 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA

NCBI chr21:26,917,922...26,967,088
Ensembl chr21:26,917,922...26,967,088

G

adenylate cyclase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA

NCBI chr 5:7,396,138...7,830,081
Ensembl chr 5:7,396,138...7,830,081

G

adenylate cyclase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA

NCBI chr14:24,318,359...24,335,071
Ensembl chr14:24,318,349...24,335,093

G

adenylate cyclase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA

NCBI chr12:48,766,194...48,789,974
Ensembl chr12:48,766,194...48,789,089

G

adenylate cyclase 7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA
Dextran Sulfate results in decreased expression of ADCY7 mRNA

PMID:29950665 PMID:35093514

NCBI chr16:50,244,699...50,318,135
Ensembl chr16:50,246,137...50,318,135

G

adenylate cyclase activating polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA

NCBI chr18:904,411...912,172
Ensembl chr18:904,871...912,172

G

ADCYAP receptor type I

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA

NCBI chr 7:31,052,308...31,111,474
Ensembl chr 7:31,052,308...31,111,474

G

adhesion G protein-coupled receptor A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA

NCBI chr 8:37,796,883...37,844,896
Ensembl chr 8:37,784,191...37,844,896

G

adhesion G protein-coupled receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA

NCBI chr 8:142,449,649...142,545,007
Ensembl chr 8:142,449,430...142,545,009

G

adhesion G protein-coupled receptor E1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ADGRE1 protein
flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein]

NCBI chr19:6,887,579...6,940,450
Ensembl chr19:6,887,566...6,940,459

G

adhesion G protein-coupled receptor E5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA

NCBI chr19:14,381,444...14,408,723
Ensembl chr19:14,380,501...14,408,725

G

adhesion G protein-coupled receptor F1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA

NCBI chr 6:46,997,708...47,042,332
Ensembl chr 6:46,997,708...47,042,350

G

adhesion G protein-coupled receptor F5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA

NCBI chr 6:46,852,522...46,954,939
Ensembl chr 6:46,852,522...46,954,943

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA

NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746

G

alcohol dehydrogenase 5 (class III), chi polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA

NCBI chr 4:99,070,978...99,088,788
Ensembl chr 4:99,070,978...99,088,801

G

adrenomedullin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA
Dextran Sulfate results in increased expression of ADM mRNA

PMID:29950665 PMID:35093514

NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397

G

adenosine A2a receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA

NCBI chr22:24,423,597...24,442,357
Ensembl chr22:24,417,879...24,442,357

G

adenosine A2b receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA

NCBI chr17:15,850,362...15,975,746
Ensembl chr17:15,945,130...15,975,746

G

adenosine A3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA

NCBI chr 1:111,499,429...111,503,633
Ensembl chr 1:111,499,429...111,503,633

G

adrenoceptor alpha 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA

NCBI chr10:111,077,029...111,080,907
Ensembl chr10:111,077,029...111,080,907

G

adrenoceptor beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA

PMID:26271895 PMID:29950665

NCBI chr 5:148,826,611...148,828,623
Ensembl chr 5:148,826,611...148,828,623

G

angiotensinogen

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA
Dextran Sulfate results in decreased expression of AGT mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576

G

AHNAK nucleoprotein

decreases expression

Dextran Sulfate results in decreased expression of AHNAK mRNA

NCBI chr11:62,433,544...62,546,806
Ensembl chr11:62,433,542...62,556,235

G

aryl hydrocarbon receptor

increases response to substance
multiple interactions

AHR gene mutant form results in increased susceptibility to Dextran Sulfate
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

alpha hemoglobin stabilizing protein

decreases expression

Dextran Sulfate results in decreased expression of AHSP protein

NCBI chr16:31,527,900...31,528,803
Ensembl chr16:31,527,900...31,528,803

G

adenylate kinase 1

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein
Dextran Sulfate results in decreased expression of AK1 protein

NCBI chr 9:127,866,480...127,879,621
Ensembl chr 9:127,866,486...127,877,675

G

A-kinase anchoring protein 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA

NCBI chr 6:151,239,967...151,358,559
Ensembl chr 6:151,239,967...151,358,559

G

A-kinase anchoring protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA

NCBI chr14:64,465,499...64,474,503
Ensembl chr14:64,465,499...64,474,503

G

aldo-keto reductase family 1 member B

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of AKR1B1 protein
Dextran Sulfate results in increased expression of AKR1B1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284

G

aldo-keto reductase family 1 member C3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA

NCBI chr10:5,048,781...5,107,686
Ensembl chr10:5,035,354...5,107,686

G

AKT serine/threonine kinase 1

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]

PMID:26262998 PMID:36806191

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759

G

albumin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA

PMID:29950665 PMID:35999755

NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482

G

aldehyde dehydrogenase 1 family member A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA

NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442

G

aldehyde dehydrogenase 1 family member B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA

NCBI chr 9:38,392,702...38,398,661
Ensembl chr 9:38,392,702...38,398,661

G

aldehyde dehydrogenase 2 family member

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA

NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532

G

aldehyde dehydrogenase 3 family member A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA

NCBI chr17:19,648,136...19,677,596
Ensembl chr17:19,648,136...19,685,760

G

aldehyde dehydrogenase 7 family member A1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ALDH7A1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein]

NCBI chr 5:126,541,841...126,595,219
Ensembl chr 5:126,531,200...126,595,362

G

aldolase, fructose-bisphosphate C

decreases expression

Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA

PMID:35093514 PMID:35999755

NCBI chr17:28,573,120...28,576,895
Ensembl chr17:28,573,115...28,576,948

G

arachidonate 12-lipoxygenase, 12S type

decreases expression

Dextran Sulfate results in decreased expression of ALOX12 protein

NCBI chr17:6,996,049...7,010,754
Ensembl chr17:6,996,049...7,010,754

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA

NCBI chr17:8,072,636...8,087,716
Ensembl chr17:8,072,636...8,087,716

G

arachidonate 5-lipoxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA

NCBI chr10:45,374,216...45,446,117
Ensembl chr10:45,374,176...45,446,119

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA

NCBI chr13:30,713,485...30,764,426
Ensembl chr13:30,713,478...30,764,426

G

alkaline phosphatase, biomineralization associated

multiple interactions
increases activity

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA
Dextran Sulfate results in increased activity of ALPL protein

PMID:29950665 PMID:30489199

NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410

G

angiopoietin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA

NCBI chr20:869,900...916,334
Ensembl chr20:869,900...916,334

G

angiopoietin like 4

increases expression

Dextran Sulfate results in increased expression of ANGPTL4 mRNA

NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370

G

anoctamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA

NCBI chr11:69,965,997...70,189,530
Ensembl chr11:69,985,907...70,189,530

G

anoctamin 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA

NCBI chr 3:43,365,848...43,691,594
Ensembl chr 3:43,354,859...43,691,594

G

anoctamin 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA

NCBI chr12:45,216,095...45,440,404
Ensembl chr12:45,215,987...45,482,280

G

anoctamin 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA

NCBI chr 2:241,188,677...241,240,308
Ensembl chr 2:241,188,509...241,225,976

G

anoctamin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA

NCBI chr11:417,938...442,011
Ensembl chr11:417,933...442,011

G

annexin A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA

NCBI chr 9:73,151,865...73,170,393
Ensembl chr 9:73,151,865...73,170,629

G

annexin A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA

NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112

G

adaptor related protein complex 1 subunit mu 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA

NCBI chr19:16,197,911...16,245,906
Ensembl chr19:16,197,854...16,245,906

G

adaptor related protein complex 1 subunit sigma 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein]

NCBI chr 7:101,154,476...101,161,276
Ensembl chr 7:101,154,456...101,161,596

G

APC regulator of WNT signaling pathway

affects response to substance
multiple interactions

APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate
[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]

PMID:16049979 PMID:26262998 PMID:30188895

NCBI chr 5:112,707,498...112,846,239
Ensembl chr 5:112,707,518...112,846,239

G

amyloid P component, serum

increases expression

Dextran Sulfate results in increased expression of APCS protein

NCBI chr 1:159,587,826...159,588,865
Ensembl chr 1:159,587,826...159,588,865

G

apelin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA
Dextran Sulfate results in decreased expression of APLN mRNA

PMID:29950665 PMID:35093514

NCBI chr X:129,645,259...129,654,956
Ensembl chr X:129,645,259...129,654,956

G

apolipoprotein A2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein

NCBI chr 1:161,222,292...161,223,628
Ensembl chr 1:161,222,290...161,223,631

G

apolipoprotein A4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of APOA4 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein]

PMID:32272095 PMID:35999755

NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304

G

apolipoprotein B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA

NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073

G

apolipoprotein C2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein

NCBI chr19:44,946,051...44,949,565
Ensembl chr19:44,946,035...44,949,565

G

apolipoprotein E

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein]

NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393

G

amyloid beta precursor protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA

NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128

G

aquaporin 1 (Colton blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA

NCBI chr 7:30,911,853...30,925,516
Ensembl chr 7:30,911,853...30,925,517

G

aquaporin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA

NCBI chr11:77,589,953...77,610,356
Ensembl chr11:77,589,391...77,610,356

G

aquaporin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA

NCBI chr12:49,950,737...49,958,878
Ensembl chr12:49,950,737...49,958,878

G

aquaporin 3 (Gill blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA

NCBI chr 9:33,441,160...33,447,593
Ensembl chr 9:33,441,156...33,447,596

G

aquaporin 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA

NCBI chr16:25,216,947...25,228,932
Ensembl chr16:25,215,731...25,228,932

G

aquaporin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA

NCBI chr15:58,138,169...58,185,911
Ensembl chr15:58,138,169...58,185,911

G

androgen receptor

increases expression
multiple interactions

Dextran Sulfate results in increased expression of AR mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA

PMID:27920257 PMID:29950665

NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619

G

ARF GTPase 3

decreases expression

Dextran Sulfate results in decreased expression of ARF3 protein

NCBI chr12:48,935,723...48,957,487
Ensembl chr12:48,935,723...48,957,487

G

arginase 1

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein]
Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein

PMID:25026504 PMID:38164749

NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332

G

Rho GTPase activating protein 1

decreases expression

Dextran Sulfate results in decreased expression of ARHGAP1 protein

NCBI chr11:46,677,080...46,700,619
Ensembl chr11:46,677,080...46,700,619

G

Rho GTPase activating protein 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA

NCBI chr 2:143,129,419...143,768,352
Ensembl chr 2:143,091,362...143,768,352

G

Rho GTPase activating protein 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA

NCBI chr11:110,577,043...110,713,189
Ensembl chr11:110,577,042...110,713,189

G

Rho GTPase activating protein 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA

NCBI chr 2:68,710,544...68,826,833
Ensembl chr 2:68,679,601...68,826,833

G

Rho GTPase activating protein 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA

NCBI chr20:38,601,809...38,650,653
Ensembl chr20:38,601,809...38,651,035

G

Rho GDP dissociation inhibitor alpha

decreases expression

Dextran Sulfate results in decreased expression of ARHGDIA protein

NCBI chr17:81,867,721...81,871,337
Ensembl chr17:81,867,719...81,871,378

G

Rho GDP dissociation inhibitor beta

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of ARHGDIB mRNA
Dextran Sulfate results in decreased expression of ARHGDIB protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA

PMID:23894361 PMID:29950665 PMID:35999755

NCBI chr12:14,942,015...14,961,601
Ensembl chr12:14,942,031...14,961,728

G

Rho guanine nucleotide exchange factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA

NCBI chr19:41,883,184...41,930,141
Ensembl chr19:41,883,173...41,930,150

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA

NCBI chr11:120,336,413...120,489,937
Ensembl chr11:120,336,413...120,489,937

G

Rac/Cdc42 guanine nucleotide exchange factor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA

NCBI chr X:136,665,550...136,780,932
Ensembl chr X:136,665,547...136,780,932

G

ARF like GTPase 3

increases expression

Dextran Sulfate results in increased expression of ARL3 mRNA

NCBI chr10:102,673,731...102,714,397
Ensembl chr10:102,673,731...102,714,397

G

ARF like GTPase 9

increases expression

Dextran Sulfate results in increased expression of ARL9 mRNA

NCBI chr 4:56,505,209...56,524,453
Ensembl chr 4:56,505,209...56,524,959

G

actin related protein 2/3 complex subunit 2

decreases expression

Dextran Sulfate results in decreased expression of ARPC2 protein

NCBI chr 2:218,217,189...218,254,348
Ensembl chr 2:218,217,141...218,254,356

G

actin related protein 2/3 complex subunit 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein
Dextran Sulfate results in decreased expression of ARPC3 protein

NCBI chr12:110,434,823...110,450,337
Ensembl chr12:110,434,823...110,450,422

G

actin related protein 2/3 complex subunit 4

decreases expression

Dextran Sulfate results in decreased expression of ARPC4 protein

NCBI chr 3:9,792,518...9,807,101
Ensembl chr 3:9,792,495...9,807,101

G

arrestin beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA

NCBI chr17:4,710,632...4,721,497
Ensembl chr17:4,710,596...4,721,499

G

arylsulfatase B

decreases expression

Dextran Sulfate results in decreased expression of ARSB mRNA

NCBI chr 5:78,777,209...78,985,958
Ensembl chr 5:78,777,209...78,986,087

G

ankyrin repeat and SOCS box containing 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA

NCBI chr14:93,934,166...93,976,570
Ensembl chr14:93,934,166...93,976,739

G

acid sensing ion channel subunit family member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA

NCBI chr 2:219,507,093...219,538,772
Ensembl chr 2:219,514,170...219,538,772

G

argininosuccinate synthase 1

decreases expression

Dextran Sulfate results in decreased expression of ASS1 mRNA

NCBI chr 9:130,444,707...130,501,274
Ensembl chr 9:130,444,961...130,501,274

G

autophagy related 5

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ATG5 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA]

PMID:27611972 PMID:31676321 PMID:35439472

NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791

G

autophagy related 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ATG7 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]

NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

decreases expression

Dextran Sulfate results in decreased expression of ATIC protein

NCBI chr 2:215,312,059...215,368,592
Ensembl chr 2:215,311,956...215,349,773

G

ATPase phospholipid transporting 10A (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA

NCBI chr15:25,672,237...25,865,088
Ensembl chr15:25,677,273...25,865,184

G

ATPase phospholipid transporting 11B (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA

NCBI chr 3:182,793,504...182,921,629
Ensembl chr 3:182,793,503...182,923,011

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA

NCBI chr13:24,680,408...24,712,472
Ensembl chr13:24,680,408...24,712,472

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA

NCBI chr 1:116,373,244...116,404,774
Ensembl chr 1:116,372,668...116,410,261

G

ATPase Na+/K+ transporting subunit alpha 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA

NCBI chr19:41,966,582...41,994,230
Ensembl chr19:41,966,582...41,997,497

G

ATPase Na+/K+ transporting subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA

NCBI chr 1:160,151,603...160,186,980
Ensembl chr 1:160,151,586...160,186,980

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA

NCBI chr 1:169,106,690...169,132,719
Ensembl chr 1:169,105,697...169,310,992

G

ATPase Na+/K+ transporting subunit beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA

NCBI chr 3:141,876,643...141,926,549
Ensembl chr 3:141,876,124...141,926,549

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA

NCBI chr16:28,878,488...28,904,466
Ensembl chr16:28,878,405...28,904,466

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA

NCBI chr17:3,923,873...3,964,437
Ensembl chr17:3,923,868...3,964,464

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA

NCBI chr12:89,588,049...89,709,366
Ensembl chr12:89,588,049...89,709,366

G

ATPase secretory pathway Ca2+ transporting 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA

NCBI chr16:84,368,538...84,464,187
Ensembl chr16:84,368,527...84,464,187

G

ATPase H+/K+ transporting subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA

NCBI chr13:113,648,804...113,658,198
Ensembl chr13:113,648,804...113,658,198

G

ATPase H+ transporting V0 subunit a2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA

NCBI chr12:123,712,353...123,761,755
Ensembl chr12:123,712,353...123,761,755

G

ATPase H+ transporting V0 subunit a4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA

NCBI chr 7:138,706,294...138,798,196
Ensembl chr 7:138,706,294...138,799,560

G

ATPase H+ transporting V0 subunit d2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 8:86,098,910...86,154,225
Ensembl chr 8:85,987,323...86,154,225

G

ATPase H+ transporting V1 subunit E2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA

NCBI chr 2:46,511,847...46,542,577
Ensembl chr 2:46,490,750...46,542,577

G

ATPase H+ transporting V1 subunit F

increases expression

Dextran Sulfate results in increased expression of ATP6V1F mRNA

NCBI chr 7:128,862,856...128,865,847
Ensembl chr 7:128,862,856...128,865,847

G

ATPase H+ transporting V1 subunit G3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA

NCBI chr 1:198,523,222...198,540,945
Ensembl chr 1:198,523,222...198,540,945

G

ATPase copper transporting alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA

NCBI chr X:77,910,693...78,050,395
Ensembl chr X:77,910,690...78,050,395

G

ATPase phospholipid transporting 8B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA

NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315

G

ATPase phospholipid transporting 8B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA

NCBI chr 1:154,325,525...154,351,304
Ensembl chr 1:154,325,525...154,351,304

G

arginine vasopressin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA

NCBI chr12:63,142,759...63,151,201
Ensembl chr12:63,142,759...63,151,201

G

arginine vasopressin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA

NCBI chr 1:206,106,936...206,117,388
Ensembl chr 1:206,106,936...206,117,699

G

arginine vasopressin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA

NCBI chr X:153,902,625...153,907,166
Ensembl chr X:153,902,531...153,907,166

G

axin 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]

NCBI chr17:65,528,563...65,561,648
Ensembl chr17:65,528,563...65,561,648

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA

NCBI chr19:17,794,791...17,813,576
Ensembl chr19:17,794,828...17,813,576

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein]

NCBI chr 2:231,395,710...231,401,164
Ensembl chr 2:231,395,671...231,408,799

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA

NCBI chr19:41,425,359...41,428,730
Ensembl chr19:41,425,359...41,428,730

G

bile acid-CoA:amino acid N-acyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA

NCBI chr 9:101,360,417...101,385,006
Ensembl chr 9:101,354,182...101,385,400

G

barrier to autointegration nuclear assembly factor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein]

NCBI chr11:66,002,079...66,004,149
Ensembl chr11:66,002,228...66,004,149

G

B cell scaffold protein with ankyrin repeats 1

increases expression

Dextran Sulfate results in increased expression of BANK1 mRNA

NCBI chr 4:101,790,730...102,074,812
Ensembl chr 4:101,411,286...102,074,812

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]

PMID:24146755 PMID:37209277 PMID:38583725

NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798

G

butyrylcholinesterase

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of BCHE protein
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein

PMID:31226429 PMID:31807802

NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462

G

BCL2 apoptosis regulator

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]

PMID:25449198 PMID:37209277 PMID:38583725

NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128

G

BCL6 transcription repressor

multiple interactions

BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]

NCBI chr 3:187,721,377...187,745,468
Ensembl chr 3:187,721,377...187,745,725

G

BAF chromatin remodeling complex subunit BCL7C

increases expression

Dextran Sulfate results in increased expression of BCL7C mRNA

NCBI chr16:30,833,626...30,894,077
Ensembl chr16:30,833,626...30,894,302

G

bradykinin receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA

NCBI chr14:96,256,210...96,264,763
Ensembl chr14:96,256,210...96,268,967

G

bradykinin receptor B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA

NCBI chr14:96,204,839...96,244,164
Ensembl chr14:96,204,679...96,244,166

G

beclin 1

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350

G

bestrophin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA

NCBI chr11:61,949,821...61,965,515
Ensembl chr11:61,950,063...61,965,515

G

biglycan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA

NCBI chr X:153,494,980...153,509,546
Ensembl chr X:153,494,980...153,509,546

G

bridging integrator 2

decreases expression

Dextran Sulfate results in decreased expression of BIN2 protein

NCBI chr12:51,281,038...51,324,668
Ensembl chr12:51,281,038...51,324,668

G

baculoviral IAP repeat containing 5

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]

NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636

G

baculoviral IAP repeat containing 6

decreases expression

Dextran Sulfate results in decreased expression of BIRC6 mRNA

NCBI chr 2:32,357,023...32,618,878
Ensembl chr 2:32,357,023...32,619,571

G

bone morphogenetic protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA

NCBI chr 8:22,165,372...22,212,326
Ensembl chr 8:22,165,140...22,212,326

G

bone morphogenetic protein 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA

NCBI chr 2:68,860,909...68,871,397
Ensembl chr 2:68,860,909...68,871,397

G

bone morphogenetic protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA

NCBI chr20:57,168,753...57,266,641
Ensembl chr20:57,168,753...57,266,641

G

bone morphogenetic protein receptor type 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA

NCBI chr 4:94,757,955...95,158,450
Ensembl chr 4:94,757,955...95,158,448

G

bone morphogenetic protein receptor type 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA

NCBI chr 2:202,376,327...202,567,749
Ensembl chr 2:202,376,327...202,567,751

G

BPI fold containing family A member 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein

NCBI chr20:33,235,996...33,243,306
Ensembl chr20:33,235,995...33,243,311

G

B-box and SPRY domain containing

increases expression

Dextran Sulfate results in increased expression of BSPRY mRNA

NCBI chr 9:113,349,541...113,371,222
Ensembl chr 9:113,349,541...113,371,233

G

bone marrow stromal cell antigen 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA

NCBI chr 4:15,703,065...15,774,173
Ensembl chr 4:15,703,065...15,738,313

G

basic transcription factor 3 like 4

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein]

NCBI chr 1:52,056,295...52,090,716
Ensembl chr 1:52,056,199...52,090,716

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA

NCBI chr 7:7,157,377...7,248,616
Ensembl chr 7:7,156,934...7,248,616

G

C1GALT1 specific chaperone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA

NCBI chr X:120,625,674...120,630,054
Ensembl chr X:120,625,674...120,630,054

G

complement C1q A chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA

NCBI chr 1:22,636,463...22,639,678
Ensembl chr 1:22,635,077...22,639,678

G

complement C1q B chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA

NCBI chr 1:22,653,236...22,661,637
Ensembl chr 1:22,652,762...22,661,637

G

C1q and TNF related 6

decreases expression

Dextran Sulfate results in decreased expression of C1QTNF6 mRNA

NCBI chr22:37,180,166...37,199,423
Ensembl chr22:37,180,166...37,199,385

G

complement C1s

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA

NCBI chr12:7,060,718...7,071,032
Ensembl chr12:6,988,259...7,071,032

G

complement C3

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA

PMID:29950665 PMID:35999755

NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562

G

complement C3a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA

NCBI chr12:8,056,844...8,066,359
Ensembl chr12:8,056,844...8,066,359

G

complement C4B (Chido/Rodgers blood group)

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein]

PMID:29950665 PMID:32272095

NCBI chr 6:32,014,795...32,035,418
Ensembl chr 6:32,014,795...32,035,418

G

complement component 4 binding protein alpha

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C4BPA protein

NCBI chr 1:207,104,233...207,144,972
Ensembl chr 1:207,104,233...207,144,972

G

complement C5a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA

NCBI chr19:47,307,477...47,322,066
Ensembl chr19:47,290,023...47,322,066

G

carbonic anhydrase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA

NCBI chr 8:85,464,007...85,481,493
Ensembl chr 8:85,463,968...85,481,493

G

carbonic anhydrase 3

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein]

NCBI chr 8:85,438,859...85,449,040
Ensembl chr 8:85,373,436...85,449,040

G

carbonic anhydrase 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CA4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein]

NCBI chr17:60,149,973...60,179,021
Ensembl chr17:60,149,942...60,170,899

G

calcium binding protein 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA

NCBI chr 2:230,712,842...230,821,075
Ensembl chr 2:230,712,842...230,821,075

G

calcium voltage-gated channel subunit alpha1 F

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA

NCBI chr X:49,205,063...49,233,340
Ensembl chr X:49,205,063...49,233,371

G

calcium voltage-gated channel subunit alpha1 S

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA

NCBI chr 1:201,039,512...201,112,426
Ensembl chr 1:201,039,512...201,112,451

G

calcitonin related polypeptide alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA

NCBI chr11:14,966,668...14,972,351
Ensembl chr11:14,966,622...14,972,354

G

calcitonin related polypeptide beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA

NCBI chr11:15,073,593...15,078,637
Ensembl chr11:14,904,997...15,082,342

G

calmodulin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA

NCBI chr14:90,396,502...90,408,268
Ensembl chr14:90,396,502...90,408,268

G

calmodulin 2

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein
Dextran Sulfate results in decreased expression of CALM2 protein

NCBI chr 2:47,160,082...47,176,936
Ensembl chr 2:47,160,084...47,176,921

G

calreticulin

decreases expression

Dextran Sulfate results in decreased expression of CALR protein

NCBI chr19:12,938,609...12,944,489
Ensembl chr19:12,938,578...12,944,489

G

calcium/calmodulin dependent protein kinase II gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA

NCBI chr10:73,812,501...73,874,555
Ensembl chr10:73,812,501...73,874,591

G

calcium/calmodulin dependent protein kinase IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA

NCBI chr 5:111,223,583...111,494,886
Ensembl chr 5:111,223,653...111,494,886

G

calcium/calmodulin dependent protein kinase kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA

NCBI chr17:3,860,315...3,893,053
Ensembl chr17:3,860,315...3,894,891

G

cyclase associated actin cytoskeleton regulatory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CAP1 protein

NCBI chr 1:40,040,240...40,072,648
Ensembl chr 1:40,040,233...40,072,649

G

calpain 13

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CAPN13 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein]

NCBI chr 2:30,722,771...30,807,446
Ensembl chr 2:30,722,771...30,820,542

G

capping actin protein of muscle Z-line subunit beta

decreases expression

Dextran Sulfate results in decreased expression of CAPZB protein

NCBI chr 1:19,338,775...19,485,539
Ensembl chr 1:19,338,775...19,485,539

G

caspase 1

multiple interactions
increases expression

3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein

PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609

NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250

G

caspase 3

increases cleavage
increases activity
multiple interactions

Dextran Sulfate results in increased cleavage of CASP3 protein
Dextran Sulfate results in increased activity of CASP3 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]

PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 More...

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 8

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CASP8 protein
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein]

NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836

G

catalase

decreases activity
increases activity
multiple interactions

Dextran Sulfate results in decreased activity of CAT protein
Dextran Sulfate results in increased activity of CAT protein
[Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]

PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

caveolae associated protein 2

decreases expression

Dextran Sulfate results in decreased expression of CAVIN2 protein

NCBI chr 2:191,834,310...191,847,088
Ensembl chr 2:191,834,310...191,847,088

G

carbonyl reductase 1

decreases expression

Dextran Sulfate results in decreased expression of CBR1 protein

NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166

G

carbonyl reductase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA

NCBI chr21:36,135,079...36,146,562
Ensembl chr21:36,135,079...36,146,562

G

coiled-coil domain containing 12

increases expression

Dextran Sulfate results in increased expression of CCDC12 mRNA

NCBI chr 3:46,921,730...46,981,994
Ensembl chr 3:46,916,634...46,982,010

G

coiled-coil domain containing 124

increases expression

Dextran Sulfate results in increased expression of CCDC124 mRNA

NCBI chr19:17,933,015...17,943,985
Ensembl chr19:17,933,015...17,943,991

G

coiled-coil domain containing 13

increases expression

Dextran Sulfate results in increased expression of CCDC13 mRNA

NCBI chr 3:42,704,118...42,773,253
Ensembl chr 3:42,705,756...42,773,253

G

coiled-coil domain containing 158

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CCDC158 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein]

NCBI chr 4:76,313,039...76,421,869
Ensembl chr 4:76,312,997...76,421,868

G

coiled-coil domain containing 88B

increases expression

Dextran Sulfate results in increased expression of CCDC88B mRNA

NCBI chr11:64,340,204...64,357,534
Ensembl chr11:64,340,204...64,357,534

G

coiled-coil domain containing 9

increases expression

Dextran Sulfate results in increased expression of CCDC9 mRNA

NCBI chr19:47,256,525...47,275,723
Ensembl chr19:47,255,980...47,273,701

G

coiled-coil alpha-helical rod protein 1

increases expression

Dextran Sulfate results in increased expression of CCHCR1 mRNA

NCBI chr 6:31,142,439...31,158,197
Ensembl chr 6:31,142,439...31,158,238

G

cholecystokinin B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA

NCBI chr11:6,259,838...6,272,127
Ensembl chr11:6,259,806...6,272,127

G

C-C motif chemokine ligand 11

multiple interactions
increases expression
increases secretion

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein]

PMID:21858153 PMID:29950665 PMID:32033881

NCBI chr17:34,285,742...34,288,334
Ensembl chr17:34,285,742...34,288,334

G

C-C motif chemokine ligand 15

decreases expression
increases expression

Dextran Sulfate results in decreased expression of CCL6 mRNA
Dextran Sulfate results in increased expression of CCL6 mRNA

PMID:19645018 PMID:35093514

NCBI chr17:35,997,582...36,001,553
Ensembl chr17:35,996,440...36,001,553

G

C-C motif chemokine ligand 2

increases secretion
increases expression
multiple interactions

Dextran Sulfate results in increased secretion of CCL2 protein
Dextran Sulfate results in increased expression of CCL2 mRNA
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein]

PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 More...

NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208

G

C-C motif chemokine ligand 21

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA

NCBI chr 9:34,709,005...34,710,136
Ensembl chr 9:34,709,005...34,710,136

G

C-C motif chemokine ligand 23

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL9 mRNA
Dextran Sulfate results in increased expression of CCL9 mRNA

PMID:29950665 PMID:35093514

NCBI chr17:36,013,058...36,017,972
Ensembl chr17:36,013,056...36,017,972

G

C-C motif chemokine ligand 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA

NCBI chr 7:75,810,825...75,823,372
Ensembl chr 7:75,810,825...75,823,356

G

C-C motif chemokine ligand 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA

NCBI chr19:8,052,341...8,062,650
Ensembl chr19:8,052,318...8,062,660

G

C-C motif chemokine ligand 27

increases expression

Dextran Sulfate results in increased expression of CCL27A mRNA

NCBI chr 9:34,661,890...34,662,657
Ensembl chr 9:34,661,880...34,664,048

G

C-C motif chemokine ligand 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA

NCBI chr 5:43,356,975...43,412,391
Ensembl chr 5:43,376,645...43,412,391

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL3 mRNA
ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]

PMID:19645018 PMID:30811821 PMID:33130971

NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169

G

C-C motif chemokine ligand 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA

NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621

G

C-C motif chemokine ligand 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL7 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA]

PMID:19645018 PMID:29950665 PMID:32033881

NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242

G

C-C motif chemokine ligand 8

increases expression

Dextran Sulfate results in increased expression of CCL8 mRNA

PMID:19645018 PMID:23894361

NCBI chr17:34,319,435...34,321,402
Ensembl chr17:34,319,435...34,321,402

G

cyclin D1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]

PMID:31715269 PMID:35439472

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

C-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA

NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,864...46,360,940

G

C-C motif chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA

NCBI chr 3:32,951,644...32,956,349
Ensembl chr 3:32,951,644...32,957,120

G

C-C motif chemokine receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA

NCBI chr 3:46,370,142...46,376,206
Ensembl chr 3:46,370,946...46,376,206

G

C-C motif chemokine receptor 7

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]

NCBI chr17:40,553,769...40,565,472
Ensembl chr17:40,551,081...40,565,472

G

C-C motif chemokine receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA

NCBI chr 3:39,329,709...39,333,680
Ensembl chr 3:39,329,709...39,333,680

G

C-C motif chemokine receptor like 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA

NCBI chr 3:46,407,259...46,409,523
Ensembl chr 3:46,407,166...46,412,997

G

centriole, cilia and spindle associated protein

increases expression

Dextran Sulfate results in increased expression of CCSAP mRNA

NCBI chr 1:229,321,015...229,343,047
Ensembl chr 1:229,321,011...229,343,294

G

CD14 molecule

affects response to substance
multiple interactions

Dextran Sulfate affects the susceptibility to CD14 protein
[Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr 5:140,631,732...140,633,701
Ensembl chr 5:140,631,728...140,633,700

G

CD163 molecule

increases expression

Dextran Sulfate results in increased expression of CD163 mRNA

NCBI chr12:7,470,811...7,503,777
Ensembl chr12:7,470,811...7,503,893

G

CD177 molecule

increases expression

Dextran Sulfate results in increased expression of CD177 mRNA

NCBI chr19:43,353,686...43,366,081
Ensembl chr19:43,353,686...43,363,172

G

CD180 molecule

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CD180 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA

PMID:23894361 PMID:29950665

NCBI chr 5:67,179,613...67,196,799
Ensembl chr 5:67,179,613...67,196,799

G

CD19 molecule

increases expression

Dextran Sulfate results in increased expression of CD19 mRNA

NCBI chr16:28,931,971...28,939,342
Ensembl chr16:28,931,965...28,939,342

G

CD200 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA

NCBI chr 3:112,332,573...112,362,812
Ensembl chr 3:112,332,235...112,363,181

G

CD247 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA

NCBI chr 1:167,430,640...167,518,529
Ensembl chr 1:167,425,027...167,518,640

G

CD274 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA

NCBI chr 9:5,450,542...5,470,554
Ensembl chr 9:5,450,503...5,470,566

G

CD28 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA

NCBI chr 2:203,706,482...203,738,912
Ensembl chr 2:203,706,517...203,739,756

G

CD34 molecule

decreases expression

Dextran Sulfate results in decreased expression of CD34 mRNA

NCBI chr 1:207,880,972...207,911,125
Ensembl chr 1:207,880,972...207,911,402

G

CD4 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA

NCBI chr12:6,789,528...6,820,799
Ensembl chr12:6,786,858...6,820,799

G

CD44 molecule (IN blood group)

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA

NCBI chr11:35,139,171...35,232,402
Ensembl chr11:35,138,882...35,232,402

G

CD52 molecule

increases expression

Dextran Sulfate results in increased expression of CD52 mRNA

NCBI chr 1:26,317,958...26,320,523
Ensembl chr 1:26,317,958...26,320,523

G

CD53 molecule

increases expression

Dextran Sulfate results in increased expression of CD53 mRNA

NCBI chr 1:110,871,210...110,899,922
Ensembl chr 1:110,871,188...110,899,936

G

CD55 molecule (Cromer blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA

NCBI chr 1:207,321,678...207,360,966
Ensembl chr 1:207,321,519...207,386,804

G

CD68 molecule

increases expression

dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice

RGD

NCBI chr17:7,579,638...7,582,111
Ensembl chr17:7,579,491...7,582,111

G

CD72 molecule

increases expression

Dextran Sulfate results in increased expression of CD72 mRNA

NCBI chr 9:35,609,982...35,646,857
Ensembl chr 9:35,609,982...35,646,810

G

CD74 molecule

increases expression
decreases expression

Dextran Sulfate results in increased expression of CD74 mRNA
Dextran Sulfate results in decreased expression of CD74 mRNA

PMID:23894361 PMID:35093514

NCBI chr 5:150,401,639...150,412,910
Ensembl chr 5:150,401,637...150,412,969

G

CD79a molecule

increases expression

Dextran Sulfate results in increased expression of CD79A mRNA

NCBI chr19:41,877,279...41,881,372
Ensembl chr19:41,877,279...41,881,372

G

CD79b molecule

increases expression

Dextran Sulfate results in increased expression of CD79B mRNA

NCBI chr17:63,928,740...63,932,331
Ensembl chr17:63,928,738...63,932,336

G

CD81 molecule

decreases expression

Dextran Sulfate results in decreased expression of CD81 mRNA

NCBI chr11:2,376,180...2,397,397
Ensembl chr11:2,376,177...2,397,802

G

CD86 molecule

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein]
Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein

PMID:29950665 PMID:38164749

NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139

G

cytidine deaminase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA

NCBI chr 1:20,589,097...20,618,903
Ensembl chr 1:20,589,086...20,618,903

G

cadherin 1

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA
Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein

PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329

NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537

G

cadherin 2

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein

PMID:34273909 PMID:36543318

NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946

G

cadherin 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA

NCBI chr16:66,366,691...66,404,784
Ensembl chr16:66,366,690...66,404,784

G

cadherin related family member 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein]

NCBI chr 5:176,542,511...176,595,974
Ensembl chr 5:176,542,511...176,595,974

G

cyclin dependent kinase 11B

increases expression

Dextran Sulfate results in increased expression of CDK11B mRNA

NCBI chr 1:1,635,225...1,659,004
Ensembl chr 1:1,635,225...1,659,012

G

cyclin dependent kinase inhibitor 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA

NCBI chr11:2,883,218...2,885,775
Ensembl chr11:2,883,213...2,885,775

G

caudal type homeobox 2

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of CDX2 protein
Dextran Sulfate results in decreased expression of CDX2 protein
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein]

PMID:29680209 PMID:38663798

NCBI chr13:27,960,918...27,969,315
Ensembl chr13:27,960,918...27,969,315

G

CCAAT enhancer binding protein delta

increases expression

Dextran Sulfate results in increased expression of CEBPD mRNA

NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164

G

carboxyl ester lipase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA

NCBI chr 9:133,061,981...133,071,861
Ensembl chr 9:133,061,981...133,071,861

G

centrosomal protein 131

increases expression

Dextran Sulfate results in increased expression of CEP131 mRNA

NCBI chr17:81,189,596...81,222,965
Ensembl chr17:81,189,593...81,222,999

G

carboxylesterase 1

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA
Dextran Sulfate results in decreased expression of CES1D mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337

G

cilia and flagella associated protein 184

increases expression

Dextran Sulfate results in increased expression of CCDC96 mRNA

NCBI chr 4:7,040,849...7,043,001
Ensembl chr 4:7,040,849...7,043,001

G

cilia and flagella associated protein 45

increases expression

Dextran Sulfate results in increased expression of CFAP45 mRNA

NCBI chr 1:159,872,364...159,900,165
Ensembl chr 1:159,872,364...159,900,165

G

complement factor B

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein

NCBI chr 6:31,946,095...31,952,084
Ensembl chr 6:31,945,650...31,952,086

G

complement factor D

increases expression

Dextran Sulfate results in increased expression of CFD protein

NCBI chr19:859,664...863,641
Ensembl chr19:859,453...867,884

G

complement factor H

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein]
Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein

PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755

NCBI chr 1:196,652,043...196,747,504
Ensembl chr 1:196,651,754...196,752,476

G

cofilin 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CFL1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein

NCBI chr11:65,854,673...65,858,180
Ensembl chr11:65,823,022...65,862,026

G

CASP8 and FADD like apoptosis regulator

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]

NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687

G

CF transmembrane conductance regulator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA

NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971

G

cell growth regulator with EF-hand domain 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein

NCBI chr 2:27,099,353...27,119,128
Ensembl chr 2:27,098,889...27,119,128

G

chromatin assembly factor 1 subunit A

increases expression

Dextran Sulfate results in increased expression of CHAF1A mRNA

NCBI chr19:4,402,640...4,450,830
Ensembl chr19:4,402,640...4,445,018

G

calcium homeostasis endoplasmic reticulum protein

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHERP protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein]

NCBI chr19:16,517,894...16,542,437
Ensembl chr19:16,517,894...16,542,437

G

charged multivesicular body protein 2A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHMP2A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein]

NCBI chr19:58,551,566...58,555,105
Ensembl chr19:58,551,452...58,555,105

G

charged multivesicular body protein 4B

increases expression

Dextran Sulfate results in increased expression of CHMP4B mRNA

NCBI chr20:33,811,348...33,854,366
Ensembl chr20:33,811,348...33,854,366

G

chimerin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA

NCBI chr 7:29,146,591...29,514,328
Ensembl chr 7:29,146,547...29,514,328

G

chordin like 2

increases expression

Dextran Sulfate results in increased expression of CHRDL2 mRNA

NCBI chr11:74,696,429...74,731,426
Ensembl chr11:74,696,429...74,731,426

G

cholinergic receptor muscarinic 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA

NCBI chr11:46,383,789...46,391,776
Ensembl chr11:46,383,789...46,391,776

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA

NCBI chr 8:27,459,756...27,479,261
Ensembl chr 8:27,459,756...27,479,883

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA

NCBI chr15:32,030,483...32,173,018
Ensembl chr15:31,923,438...32,173,018

G

cholinergic receptor nicotinic beta 3 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA

NCBI chr 8:42,697,366...42,737,407
Ensembl chr 8:42,697,366...42,737,407

G

cholinergic receptor nicotinic epsilon subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA

NCBI chr17:4,897,771...4,908,677
Ensembl chr17:4,897,771...4,934,438

G

carbohydrate sulfotransferase 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA

NCBI chr12:104,456,948...104,762,014
Ensembl chr12:104,455,295...104,762,014

G

component of inhibitor of nuclear factor kappa B kinase complex

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CHUK protein modified form
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form]

NCBI chr10:100,186,319...100,229,596
Ensembl chr10:100,188,300...100,229,596

G

creatine kinase B

decreases expression

Dextran Sulfate results in decreased expression of CKB protein

NCBI chr14:103,519,667...103,522,830
Ensembl chr14:103,519,667...103,522,833

G

creatine kinase, M-type

decreases expression

Dextran Sulfate results in decreased expression of CKM protein

NCBI chr19:45,306,413...45,322,875
Ensembl chr19:45,306,413...45,322,875

G

chloride channel accessory 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA

NCBI chr 1:86,468,927...86,500,259
Ensembl chr 1:86,468,368...86,500,259

G

chloride channel accessory 4

increases expression

Dextran Sulfate results in increased expression of CLCA4 mRNA

NCBI chr 1:86,547,078...86,580,754
Ensembl chr 1:86,547,078...86,580,754

G

chloride voltage-gated channel 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA

NCBI chr 3:184,346,185...184,361,605
Ensembl chr 3:184,346,185...184,361,650

G

chloride voltage-gated channel 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA

NCBI chr 4:169,620,578...169,723,673
Ensembl chr 4:169,612,633...169,723,673

G

claudin 1

multiple interactions
increases expression
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]

PMID:27920472 PMID:36543318 PMID:37001609 PMID:38648921

NCBI chr 3:190,305,707...190,322,446
Ensembl chr 3:190,305,707...190,322,446

G

claudin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA

NCBI chr 3:170,418,868...170,434,691
Ensembl chr 3:170,418,868...170,454,733

G

claudin 2

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA
Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein

PMID:26271895 PMID:29680209 PMID:36543318

NCBI chr X:106,900,164...106,930,861
Ensembl chr X:106,900,164...106,930,861

G

C-type lectin domain containing 10A

increases expression

Dextran Sulfate results in increased expression of CLEC10A mRNA

NCBI chr17:7,074,537...7,080,251
Ensembl chr17:7,074,537...7,080,307

G

chloride intracellular channel 1

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein
Dextran Sulfate results in decreased expression of CLIC1 protein

NCBI chr 6:31,730,581...31,737,318
Ensembl chr 6:31,730,581...31,739,763

G

chymase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA

NCBI chr14:24,505,353...24,508,265
Ensembl chr14:24,505,353...24,508,265

G

cytidine monophosphate N-acetylneuraminic acid synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA

NCBI chr12:22,046,218...22,065,668
Ensembl chr12:22,046,218...22,065,674

G

cytidine/uridine monophosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of CMPK1 protein

NCBI chr 1:47,333,790...47,378,839
Ensembl chr 1:47,333,790...47,394,866

G

cyclic nucleotide gated channel subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA

NCBI chr11:6,234,793...6,244,976
Ensembl chr11:6,234,765...6,244,479

G

calponin 2

decreases expression

Dextran Sulfate results in decreased expression of CNN2 protein

NCBI chr19:1,026,608...1,039,065
Ensembl chr19:1,026,586...1,039,068

G

cannabinoid receptor 1

decreases response to substance
multiple interactions
increases expression

CNR1 results in decreased susceptibility to Dextran Sulfate
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]

PMID:15085199 PMID:27920472 PMID:30611738

NCBI chr 6:88,139,864...88,167,349
Ensembl chr 6:88,139,864...88,166,347

G

cannabinoid receptor 2

multiple interactions
increases response to substance
increases expression
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein]
CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate
CNR2 protein affects the susceptibility to Dextran Sulfate

PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172

NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362

G

ciliary neurotrophic factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA

NCBI chr 9:34,551,433...34,590,852
Ensembl chr 9:34,551,432...34,590,140

G

contactin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA

NCBI chr12:40,692,439...41,072,415
Ensembl chr12:40,692,439...41,072,415

G

component of oligomeric golgi complex 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COG1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein]

NCBI chr17:73,193,055...73,208,507
Ensembl chr17:73,193,055...73,208,507

G

collagen type XI alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA

NCBI chr 1:102,876,473...103,108,522
Ensembl chr 1:102,876,467...103,108,872

G

collagen type XIV alpha 1 chain

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein]

PMID:29950665 PMID:32272095

NCBI chr 8:120,124,454...120,373,573
Ensembl chr 8:120,059,780...120,373,573

G

collagen type XVI alpha 1 chain

increases expression

Dextran Sulfate results in increased expression of COL16A1 mRNA

NCBI chr 1:31,652,263...31,704,017
Ensembl chr 1:31,652,263...31,704,319

G

collagen type XVIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA

NCBI chr21:45,405,165...45,513,720
Ensembl chr21:45,405,165...45,513,720

G

collagen type I alpha 1 chain

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA
Dextran Sulfate results in decreased expression of COL1A1 mRNA

PMID:29950665 PMID:35093514

NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632

G

collagen type I alpha 2 chain

decreases expression

Dextran Sulfate results in decreased expression of COL1A2 mRNA

NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227

G

collagen type XXII alpha 1 chain

increases expression

Dextran Sulfate results in increased expression of COL22A1 mRNA

NCBI chr 8:138,588,235...138,914,041
Ensembl chr 8:138,588,235...138,914,041

G

collagen type XXIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA

NCBI chr 5:178,237,618...178,590,393
Ensembl chr 5:178,237,476...178,590,393

G

collagen type XXVIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA

NCBI chr 7:7,338,194...7,543,870
Ensembl chr 7:7,356,203...7,535,873

G

collagen type III alpha 1 chain

decreases expression

Dextran Sulfate results in decreased expression of COL3A1 mRNA

NCBI chr 2:188,974,373...189,012,746
Ensembl chr 2:188,974,373...189,012,746

G

collagen type IV alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA

NCBI chr13:110,148,963...110,307,157
Ensembl chr13:110,148,963...110,307,202

G

collagen type IV alpha 2 chain

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein]

PMID:29950665 PMID:32272095

NCBI chr13:110,307,284...110,513,209
Ensembl chr13:110,305,812...110,513,209

G

collagen type V alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA

NCBI chr 9:134,641,803...134,844,843
Ensembl chr 9:134,641,803...134,844,843

G

collagen type V alpha 2 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA

NCBI chr 2:189,031,898...189,441,111
Ensembl chr 2:189,031,898...189,225,312

G

collagen type VI alpha 1 chain

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein]
Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein

PMID:32272095 PMID:35093514

NCBI chr21:45,981,770...46,005,048
Ensembl chr21:45,981,770...46,005,050

G

collagen type VI alpha 2 chain

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein]

PMID:32272095 PMID:35093514

NCBI chr21:46,098,112...46,132,848
Ensembl chr21:46,098,112...46,132,848

G

collagen type VI alpha 4 pseudogene 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A4 protein]

NCBI chr 3:15,165,362...15,205,959
Ensembl chr 3:15,151,833...15,180,961
Ensembl chr 3:15,151,833...15,180,961

G

collagen type VIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA

NCBI chr 3:99,638,594...99,799,217
Ensembl chr 3:99,638,475...99,799,226

G

coronin 1A

decreases expression

Dextran Sulfate results in decreased expression of CORO1A protein

NCBI chr16:30,183,602...30,189,076
Ensembl chr16:30,182,827...30,189,076

G

coronin 1C

decreases expression

Dextran Sulfate results in decreased expression of CORO1C protein

NCBI chr12:108,645,109...108,731,518
Ensembl chr12:108,645,109...108,731,526

G

coactosin like F-actin binding protein 1

decreases expression

Dextran Sulfate results in decreased expression of COTL1 protein

NCBI chr16:84,565,596...84,618,078
Ensembl chr16:84,565,596...84,618,078

G

cytochrome c oxidase subunit 5B

increases expression

Dextran Sulfate results in increased expression of COX5B mRNA

NCBI chr 2:97,646,062...97,648,383
Ensembl chr 2:97,646,062...97,648,383

G

ceruloplasmin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA

NCBI chr 3:149,162,414...149,221,829
Ensembl chr 3:149,162,410...149,221,829

G

carboxypeptidase A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA

NCBI chr 7:130,380,494...130,388,108
Ensembl chr 7:130,380,339...130,388,114

G

carboxypeptidase B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA

NCBI chr13:46,053,186...46,105,033
Ensembl chr13:46,053,186...46,105,033

G

complement C3d receptor 2

increases expression

Dextran Sulfate results in increased expression of CR2 mRNA

NCBI chr 1:207,454,328...207,489,892
Ensembl chr 1:207,453,024...207,489,895

G

capping protein inhibiting regulator of actin dynamics

increases expression

Dextran Sulfate results in increased expression of CRACD mRNA

NCBI chr 4:56,049,098...56,330,609
Ensembl chr 4:56,049,098...56,330,609

G

corticotropin releasing hormone receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA

NCBI chr17:45,784,320...45,835,828
Ensembl chr17:45,784,277...45,835,828

G

corticotropin releasing hormone receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA

NCBI chr 7:30,651,942...30,700,103
Ensembl chr 7:30,651,942...30,700,129

G

cysteine rich secretory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CRISP1 protein

NCBI chr 6:49,834,257...49,877,096
Ensembl chr 6:49,834,257...49,877,096

G

cartilage associated protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA

NCBI chr 3:33,114,014...33,147,773
Ensembl chr 3:33,114,014...33,147,773

G

colony stimulating factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA

NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992

G

colony stimulating factor 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]

PMID:15652231 PMID:29950665 PMID:31442584

NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170

G

colony stimulating factor 2 receptor subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA

NCBI chr22:36,913,628...36,940,439
Ensembl chr22:36,913,628...36,940,439

G

colony stimulating factor 3

multiple interactions
increases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA]

NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813

G

colony stimulating factor 3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA

NCBI chr 1:36,466,043...36,483,314
Ensembl chr 1:36,466,043...36,483,278

G

catenin beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTNNB1 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]

PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269

NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096

G

CTP synthase 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein]

NCBI chr 1:40,979,696...41,012,565
Ensembl chr 1:40,979,300...41,012,565

G

cathepsin C

decreases expression

Dextran Sulfate results in decreased expression of CTSC mRNA

NCBI chr11:88,293,592...88,337,736
Ensembl chr11:88,265,069...88,359,684

G

cathepsin D

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTSD protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein]

NCBI chr11:1,752,755...1,763,927
Ensembl chr11:1,752,752...1,764,573

G

cathepsin K

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA

NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,794,880...150,809,577

G

cathepsin L

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA

PMID:29950665 PMID:35999755

NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469

G

cathepsin S

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTSS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein]

NCBI chr 1:150,730,188...150,765,778
Ensembl chr 1:150,730,079...150,765,957

G

cubilin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA

NCBI chr10:16,823,966...17,129,811
Ensembl chr10:16,823,966...17,129,811

G

C-X3-C motif chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA

NCBI chr 3:39,263,494...39,292,966
Ensembl chr 3:39,263,495...39,281,735

G

CXADR Ig-like cell adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA

NCBI chr21:17,513,043...17,636,262
Ensembl chr21:17,513,043...17,593,579

G

C-X-C motif chemokine ligand 1

multiple interactions
increases secretion
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein]
Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein

PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 More...

NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308

G

C-X-C motif chemokine ligand 10

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 12

decreases expression

Dextran Sulfate results in decreased expression of CXCL12 mRNA

NCBI chr10:44,370,165...44,385,097
Ensembl chr10:44,370,165...44,386,493

G

C-X-C motif chemokine ligand 13

increases expression

Dextran Sulfate results in increased expression of CXCL13 mRNA

PMID:23894361 PMID:35093514

NCBI chr 4:77,511,753...77,611,834
Ensembl chr 4:77,511,753...77,611,834

G

C-X-C motif chemokine ligand 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA

NCBI chr 5:135,570,679...135,578,991
Ensembl chr 5:135,570,679...135,579,279

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]
Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein

PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841

NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196

G

C-X-C motif chemokine ligand 6

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA
Dextran Sulfate results in increased expression of CXCL5 mRNA

PMID:19645018 PMID:29950665

NCBI chr 4:73,836,678...73,838,760
Ensembl chr 4:73,836,640...73,849,064

G

C-X-C motif chemokine ligand 8

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CXCL15 protein; Dextran Sulfate results in increased expression of CXCL8 protein
Dextran Sulfate results in increased expression of CXCL8 mRNA
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]

PMID:20637373 PMID:32272095 PMID:38423481

NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716

G

C-X-C motif chemokine ligand 9

increases expression

Dextran Sulfate results in increased expression of CXCL9 mRNA

NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509

G

C-X-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA

NCBI chr 2:218,125,294...218,137,251
Ensembl chr 2:218,125,289...218,137,251

G

cytochrome b-245 alpha chain

increases expression

Dextran Sulfate results in increased expression of CYBA protein

NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083

G

cytochrome b-245 beta chain

increases expression

Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein

PMID:20637373 PMID:23894361

NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461

G

cytoplasmic FMR1 interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA

NCBI chr15:22,867,052...22,980,898
Ensembl chr15:22,867,052...22,981,063

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA

NCBI chr 5:157,266,123...157,395,594
Ensembl chr 5:157,266,079...157,395,595

G

cytochrome P450 family 11 subfamily A member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr15:74,337,762...74,367,646
Ensembl chr15:74,337,759...74,367,646

G

cytochrome P450 family 17 subfamily A member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP17A1 mRNA

NCBI chr10:102,830,531...102,837,413
Ensembl chr10:102,830,531...102,837,472

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions
decreases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein

PMID:29680209 PMID:34998820

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP1A2 protein
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 21 subfamily A member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP21A1 mRNA

NCBI chr 6:32,038,415...32,041,644
Ensembl chr 6:32,038,327...32,041,644

G

cytochrome P450 family 24 subfamily A member 1

increases expression

Dextran Sulfate results in increased expression of CYP24A1 protein

NCBI chr20:54,143,538...54,173,986
Ensembl chr20:54,153,446...54,173,986

G

cytochrome P450 family 26 subfamily B member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP26B1 mRNA

NCBI chr 2:72,129,238...72,147,862
Ensembl chr 2:72,129,238...72,147,862

G

cytochrome P450 family 27 subfamily B member 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA
Dextran Sulfate results in decreased expression of CYP27B1 protein

PMID:29950665 PMID:38588969

NCBI chr12:57,762,334...57,767,078
Ensembl chr12:57,762,334...57,768,986

G

cytochrome P450 family 2 subfamily B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA

NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398

G

cytochrome P450 family 2 subfamily C member 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C38 mRNA

NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547

G

cytochrome P450 family 2 subfamily C member 23, pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2C23 mRNA

NCBI chr10:100,105,754...100,140,151
Ensembl chr10:100,105,754...100,140,151

G

cytochrome P450 family 2 subfamily C member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA

NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497

G

cytochrome P450 family 2 subfamily C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C65 mRNA

NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091

G

cytochrome P450 family 2 subfamily E member 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2E1 protein
[Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone

NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220

G

cytochrome P450 family 2 subfamily J member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA

NCBI chr 1:59,893,308...59,969,212
Ensembl chr 1:59,893,308...59,926,773

G

cytochrome P450 family 2 subfamily R member 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein]

PMID:29950665 PMID:38588969

NCBI chr11:14,877,440...14,892,443
Ensembl chr11:14,877,440...14,892,231

G

cytochrome P450 family 2 subfamily S member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA

NCBI chr19:41,193,219...41,207,539
Ensembl chr19:41,193,210...41,207,539

G

cytochrome P450 family 3 subfamily A member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA

NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996

G

cytochrome P450 family 4 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA

NCBI chr 1:46,799,046...46,819,413
Ensembl chr 1:46,757,838...46,819,413

G

cytochrome P450 family 4 subfamily F member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA

NCBI chr19:15,673,087...15,697,174
Ensembl chr19:15,673,018...15,697,174

G

cytochrome P450 family 4 subfamily F member 22

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA

NCBI chr19:15,508,525...15,552,317
Ensembl chr19:15,508,525...15,552,317

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP7A1 mRNA

NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737

G

dihydrolipoamide branched chain transacylase E2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of DBT protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein]

NCBI chr 1:100,186,919...100,249,834
Ensembl chr 1:100,186,919...100,249,834

G

decorin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein]

PMID:29950665 PMID:32272095

NCBI chr12:91,140,484...91,182,817
Ensembl chr12:91,140,484...91,183,217

G

discoidin domain receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA

NCBI chr 1:162,630,863...162,787,405
Ensembl chr 1:162,631,373...162,787,405

G

DEPP autophagy regulator 1

increases expression

Dextran Sulfate results in increased expression of DEPP1 mRNA

NCBI chr10:44,976,128...44,978,809
Ensembl chr10:44,970,981...44,978,809

G

derlin 3

increases expression

Dextran Sulfate results in increased expression of DERL3 mRNA

NCBI chr22:23,834,503...23,839,006
Ensembl chr22:23,834,503...23,839,128

G

diacylglycerol kinase beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA

NCBI chr 7:14,145,049...14,974,858
Ensembl chr 7:14,145,049...14,974,777

G

diacylglycerol kinase iota

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA

NCBI chr 7:137,381,037...137,846,974
Ensembl chr 7:137,381,037...137,847,092

G

24-dehydrocholesterol reductase

decreases expression

Dextran Sulfate results in decreased expression of DHCR24 mRNA

NCBI chr 1:54,849,627...54,887,195
Ensembl chr 1:54,849,627...54,887,195

G

dehydrogenase/reductase 9

increases expression

Dextran Sulfate results in increased expression of DHRS9 mRNA

NCBI chr 2:169,067,077...169,096,167
Ensembl chr 2:169,064,789...169,096,167

G

dehydrogenase/reductase X-linked

increases expression

Dextran Sulfate results in increased expression of DHRSX mRNA

NCBI chr  X:2,219,506...2,500,976
NCBI chr  Y:2,219,506...2,500,976
Ensembl chr  X:2,219,506...2,502,805
Ensembl chr  Y:2,219,506...2,502,805

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]

NCBI chr 4:106,921,802...107,036,313
Ensembl chr 4:106,921,802...107,283,806

G

delta like non-canonical Notch ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA

NCBI chr14:100,726,892...100,738,224
Ensembl chr14:100,725,705...100,738,224

G

DM1 protein kinase

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA

NCBI chr19:45,769,717...45,782,490
Ensembl chr19:45,769,709...45,782,552

G

DMRT like family A1

decreases expression

Dextran Sulfate results in decreased expression of DMRTA1 mRNA

NCBI chr 9:22,446,824...22,455,740
Ensembl chr 9:22,446,824...22,455,740

G

DM1 locus, WD repeat containing

increases expression

Dextran Sulfate results in increased expression of DMWD mRNA

NCBI chr19:45,782,947...45,792,845
Ensembl chr19:45,782,947...45,792,845

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein]

NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,255...182,794,464

G

dynamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA

NCBI chr 9:128,203,379...128,255,244
Ensembl chr 9:128,191,655...128,255,248

G

dynamin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA

NCBI chr 1:171,841,498...172,418,466
Ensembl chr 1:171,817,887...172,418,466

G

docking protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA

NCBI chr 8:21,908,873...21,913,690
Ensembl chr 8:21,908,873...21,913,690

G

dipeptidase 1

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein]

PMID:32272095 PMID:35999755

NCBI chr16:89,613,308...89,641,540
Ensembl chr16:89,613,308...89,638,456

G

dipeptidase 2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA

PMID:29950665 PMID:35999755

NCBI chr16:67,987,390...68,000,619
Ensembl chr16:67,987,394...68,000,586

G

dihydropyrimidine dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA

NCBI chr 1:97,077,743...97,921,059
Ensembl chr 1:97,077,743...97,995,000

G

DR1 associated protein 1

increases expression

Dextran Sulfate results in increased expression of DRAP1 mRNA

NCBI chr11:65,919,426...65,921,563
Ensembl chr11:65,919,274...65,921,563

G

dopamine receptor D4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA

NCBI chr11:637,269...640,706
Ensembl chr11:637,269...640,706

G

dopamine receptor D5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA

NCBI chr 4:9,781,634...9,784,009
Ensembl chr 4:9,781,634...9,784,009

G

deltex E3 ubiquitin ligase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA

NCBI chr12:113,056,730...113,098,025
Ensembl chr12:113,056,730...113,098,028

G

dual oxidase maturation factor 2

increases expression

Dextran Sulfate results in increased expression of DUOXA2 mRNA

NCBI chr15:45,114,326...45,118,421
Ensembl chr15:45,114,326...45,118,421

G

dual specificity phosphatase 1

multiple interactions
increases expression

DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]
Dextran Sulfate results in increased expression of DUSP1 mRNA

PMID:30844440 PMID:35093514

NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195

G

enoyl-CoA delta isomerase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA

NCBI chr16:2,239,402...2,251,587
Ensembl chr16:2,239,402...2,252,300

G

Ecm29 proteasome adaptor and scaffold

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein]

NCBI chr 9:111,360,685...111,484,383
Ensembl chr 9:111,360,685...111,484,745

G

ectodysplasin A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA

NCBI chr X:69,616,113...70,039,472
Ensembl chr X:69,616,067...70,039,472

G

ectodysplasin A2 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA

NCBI chr X:66,595,637...66,639,269
Ensembl chr X:66,595,637...66,639,298

G

endothelial differentiation related factor 1

increases expression

Dextran Sulfate results in increased expression of EDF1 mRNA

NCBI chr 9:136,862,119...136,866,308
Ensembl chr 9:136,862,119...136,866,308

G

endothelin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

endothelin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of EDN2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA

PMID:16216902 PMID:29950665

NCBI chr 1:41,478,775...41,484,683
Ensembl chr 1:41,478,775...41,484,683

G

endothelin receptor type A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA

NCBI chr 4:147,481,097...147,544,954
Ensembl chr 4:147,480,917...147,544,954

G

eukaryotic translation elongation factor 1 gamma

decreases expression

Dextran Sulfate results in decreased expression of EEF1G protein

NCBI chr11:62,559,596...62,573,891
Ensembl chr11:62,559,596...62,574,086

G

EGF containing fibulin extracellular matrix protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA

NCBI chr11:65,866,441...65,872,800
Ensembl chr11:65,866,441...65,873,592

G

EF-hand domain family member D2

increases expression

Dextran Sulfate results in increased expression of EFHD2 mRNA

NCBI chr 1:15,409,888...15,430,339
Ensembl chr 1:15,409,888...15,430,339

G

ephrin A1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA

NCBI chr 1:155,127,876...155,134,899
Ensembl chr 1:155,127,876...155,134,899

G

egl-9 family hypoxia inducible factor 2

increases expression

Dextran Sulfate results in increased expression of EGLN2 mRNA

NCBI chr19:40,799,191...40,808,434
Ensembl chr19:40,798,996...40,808,434

G

EH domain containing 1

decreases expression

Dextran Sulfate results in decreased expression of EHD1 protein

NCBI chr11:64,851,642...64,879,693
Ensembl chr11:64,851,642...64,888,296

G

EH domain containing 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of EHD4 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein

NCBI chr15:41,895,933...41,972,557
Ensembl chr15:41,895,933...41,972,557

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA

NCBI chr 3:185,190,624...185,254,049
Ensembl chr 3:185,190,624...185,281,990

G

euchromatic histone lysine methyltransferase 2

increases expression

Dextran Sulfate results in increased expression of EHMT2 mRNA

NCBI chr 6:31,879,759...31,897,698
Ensembl chr 6:31,879,759...31,897,698

G

eukaryotic translation initiation factor 2 alpha kinase 2

increases phosphorylation
multiple interactions

Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein
EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein]

NCBI chr 2:37,099,210...37,156,980
Ensembl chr 2:37,099,210...37,157,522

G

eukaryotic translation initiation factor 3 subunit A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA

NCBI chr10:119,033,670...119,080,817
Ensembl chr10:119,033,670...119,080,817

G

eukaryotic translation initiation factor 5A

decreases expression

Dextran Sulfate results in decreased expression of EIF5A protein

NCBI chr17:7,306,999...7,312,463
Ensembl chr17:7,306,999...7,312,463

G

eukaryotic translation initiation factor 5B

increases expression

Dextran Sulfate results in increased expression of EIF5B mRNA

NCBI chr 2:99,337,389...99,401,326
Ensembl chr 2:99,337,389...99,401,326

G

elastase, neutrophil expressed

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA

NCBI chr19:852,303...856,243
Ensembl chr19:851,014...856,247

G

engulfment and cell motility 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA

NCBI chr20:46,366,050...46,406,615
Ensembl chr20:46,366,050...46,432,985

G

ER membrane protein complex subunit 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein]

NCBI chr 8:108,443,624...108,489,196
Ensembl chr 8:108,443,601...108,489,196

G

epithelial membrane protein 2

decreases expression

Dextran Sulfate results in decreased expression of EMP2 mRNA

NCBI chr16:10,528,422...10,580,598
Ensembl chr16:10,528,422...10,580,632

G

endoglin

decreases expression

Dextran Sulfate results in decreased expression of ENG mRNA

NCBI chr 9:127,815,016...127,854,658
Ensembl chr 9:127,811,130...127,854,773

G

enolase 1

decreases expression

Dextran Sulfate results in decreased expression of ENO1 protein

NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190

G

enolase 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein]

PMID:32272095 PMID:35999755

NCBI chr17:4,948,710...4,957,129
Ensembl chr17:4,948,092...4,957,131

G

glutamyl aminopeptidase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ENPEP protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein]

NCBI chr 4:110,476,155...110,565,285
Ensembl chr 4:110,365,733...110,565,285

G

ectonucleoside triphosphate diphosphohydrolase 5 (inactive)

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA

NCBI chr14:73,955,329...74,019,288
Ensembl chr14:73,958,010...74,019,399

G

E1A binding protein p300

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA

NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,510...41,180,077

G

epoxide hydrolase 1

decreases expression

Dextran Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA

NCBI chr17:39,688,094...39,728,658
Ensembl chr17:39,687,914...39,730,426

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA

NCBI chr12:56,080,108...56,103,505
Ensembl chr12:56,076,799...56,103,505

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA

NCBI chr 2:211,375,717...212,538,802
Ensembl chr 2:211,375,717...212,538,841

G

epiregulin

decreases response to substance
increases expression

EREG protein results in decreased susceptibility to Dextran Sulfate
dextran sodium sulfate increases expression of Ereg protein in colonic mucosa

CTD
RGD

PMID:15456865 PMID:20498653

NCBI chr 4:74,365,145...74,388,749
Ensembl chr 4:74,365,145...74,388,749

G

ERBB receptor feedback inhibitor 1

increases expression

Dextran Sulfate results in increased expression of ERRFI1 mRNA

NCBI chr 1:8,011,727...8,026,309
Ensembl chr 1:8,004,404...8,026,309

G

endothelial cell adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA

NCBI chr11:124,753,126...124,762,290
Ensembl chr11:124,752,583...124,762,290

G

estrogen receptor 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ESR1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA

PMID:29950665 PMID:30270565

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

estrogen receptor 2

multiple interactions

Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA]

NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112

G

Enah/Vasp-like

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA

NCBI chr14:99,971,422...100,144,236
Ensembl chr14:99,971,449...100,144,236

G

EWS RNA binding protein 1

increases expression

Dextran Sulfate results in increased expression of EWSR1 mRNA

NCBI chr22:29,268,268...29,300,521
Ensembl chr22:29,268,009...29,300,525

G

coagulation factor X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA

NCBI chr13:113,122,799...113,149,529
Ensembl chr13:113,122,799...113,149,529

G

coagulation factor XI

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein

NCBI chr 4:186,266,189...186,289,681
Ensembl chr 4:186,266,189...186,289,681

G

coagulation factor XIII A chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA

NCBI chr 6:6,144,084...6,320,662
Ensembl chr 6:6,144,084...6,321,013

G

coagulation factor II thrombin receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA

NCBI chr 5:76,716,126...76,735,770
Ensembl chr 5:76,716,126...76,735,770

G

F2R like trypsin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA

NCBI chr 5:76,819,030...76,835,315
Ensembl chr 5:76,818,933...76,835,315

G

coagulation factor V

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA

NCBI chr 1:169,511,951...169,586,481
Ensembl chr 1:169,511,951...169,586,588

G

fatty acid amide hydrolase

multiple interactions

[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein

NCBI chr 1:46,394,317...46,413,845
Ensembl chr 1:46,394,317...46,413,848

G

fatty acid binding protein 4

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein]

PMID:26271895 PMID:32272095

NCBI chr 8:81,478,419...81,483,233
Ensembl chr 8:81,478,419...81,483,236

G

fatty acid binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA

NCBI chr 5:160,187,381...160,238,722
Ensembl chr 5:160,187,367...160,238,735

G

fatty acid desaturase 1

decreases expression

Dextran Sulfate results in decreased expression of FADS1 mRNA

NCBI chr11:61,799,627...61,817,003
Ensembl chr11:61,799,627...61,829,318

G

fatty acid desaturase 2

decreases expression

Dextran Sulfate results in decreased expression of FADS2 mRNA

NCBI chr11:61,816,203...61,867,354
Ensembl chr11:61,792,980...61,867,354

G

family with sequence similarity 229 member A

increases expression

Dextran Sulfate results in increased expression of FAM229A mRNA

NCBI chr 1:32,361,270...32,362,485
Ensembl chr 1:32,361,270...32,364,278

G

family with sequence similarity 50 member B

increases expression

Dextran Sulfate results in increased expression of FAM50B mRNA

NCBI chr 6:3,831,894...3,851,317
Ensembl chr 6:3,849,373...3,851,320

G

family with sequence similarity 98 member B

increases expression

Dextran Sulfate results in increased expression of FAM98B mRNA

NCBI chr15:38,454,127...38,487,710
Ensembl chr15:38,454,127...38,487,710

G

FAU ubiquitin like and ribosomal protein S30 fusion

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FAU protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein]

NCBI chr11:65,120,630...65,122,134
Ensembl chr11:65,120,630...65,122,177

G

fibulin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA

NCBI chr 3:13,549,125...13,638,404
Ensembl chr 3:13,549,125...13,638,422

G

fibulin 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA
Dextran Sulfate results in decreased expression of FBLN5 mRNA

PMID:29950665 PMID:35093514

NCBI chr14:91,869,411...91,947,694
Ensembl chr14:91,869,411...91,947,987

G

fibrillin 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein]

PMID:29950665 PMID:32272095

NCBI chr15:48,408,313...48,645,709
Ensembl chr15:48,408,313...48,645,721

G

F-box protein 2

increases expression

Dextran Sulfate results in increased expression of FBXO2 mRNA

NCBI chr 1:11,648,387...11,654,429
Ensembl chr 1:11,637,018...11,655,785

G

Fc epsilon receptor Ig

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA

NCBI chr 1:161,215,295...161,219,245
Ensembl chr 1:161,215,234...161,220,699

G

Fc gamma receptor Ia

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA

NCBI chr 1:149,782,694...149,800,609
Ensembl chr 1:149,782,671...149,791,675

G

Fc gamma receptor IIb

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA

NCBI chr 1:161,647,243...161,678,654
Ensembl chr 1:161,663,143...161,678,654

G

Fc gamma receptor IIIa

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA

NCBI chr 1:161,541,759...161,550,737
Ensembl chr 1:161,541,759...161,550,968

G

fucose kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FCSK mRNA

NCBI chr16:70,454,595...70,480,274
Ensembl chr16:70,454,595...70,480,274

G

ferredoxin 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FDX1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein]

NCBI chr11:110,429,331...110,464,884
Ensembl chr11:110,429,948...110,464,884

G

ferredoxin reductase

decreases expression

Dextran Sulfate results in decreased expression of FDXR mRNA

NCBI chr17:74,862,497...74,872,994
Ensembl chr17:74,862,497...74,873,031

G

FERM domain containing kindlin 3

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of FERMT3 protein
Dextran Sulfate results in decreased expression of FERMT3 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein]

PMID:32272095 PMID:35999755

NCBI chr11:64,205,920...64,223,891
Ensembl chr11:64,205,926...64,223,896

G

free fatty acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA

NCBI chr19:35,448,257...35,451,767
Ensembl chr19:35,443,907...35,451,767

G

free fatty acid receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA

NCBI chr10:93,566,665...93,590,072
Ensembl chr10:93,566,665...93,604,480

G

fibroblast growth factor 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA

NCBI chr 5:171,419,647...171,457,626
Ensembl chr 5:171,419,647...171,457,626

G

fibroblast growth factor 19

multiple interactions

Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein

NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022

G

fibroblast growth factor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

fibroblast growth factor 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA

NCBI chr12:4,368,227...4,379,712
Ensembl chr12:4,368,227...4,379,712

G

fibroblast growth factor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA

NCBI chr10:101,770,109...101,780,369
Ensembl chr10:101,770,109...101,780,371

G

fibroblast growth factor 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA

NCBI chr13:21,671,073...21,704,498
Ensembl chr13:21,671,073...21,704,498

G

fibroblast growth factor receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA

NCBI chr 8:38,411,143...38,468,635
Ensembl chr 8:38,400,215...38,468,834

G

fibroblast growth factor receptor 4

increases expression

Dextran Sulfate results in increased expression of FGFR4 mRNA

NCBI chr 5:177,086,915...177,098,144
Ensembl chr 5:177,086,905...177,098,144

G

fibrinogen like 1

increases expression

Dextran Sulfate results in increased expression of FGL1 protein

NCBI chr 8:17,864,389...17,895,538
Ensembl chr 8:17,864,380...17,910,365

G

four and a half LIM domains 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FHL1 protein

NCBI chr X:136,146,702...136,211,359
Ensembl chr X:136,146,702...136,211,359

G

four and a half LIM domains 2

decreases expression

Dextran Sulfate results in decreased expression of FHL2 mRNA

NCBI chr 2:105,357,712...105,438,529
Ensembl chr 2:105,357,712...105,438,513

G

four and a half LIM domains 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FHL3 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein]

NCBI chr 1:37,996,770...38,005,514
Ensembl chr 1:37,996,764...38,005,606

G

filamin A

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FLNA protein

NCBI chr X:154,348,531...154,374,634
Ensembl chr X:154,348,524...154,374,634

G

flotillin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FLOT2 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein]

NCBI chr17:28,879,339...28,897,733
Ensembl chr17:28,879,335...28,897,733

G

fms related receptor tyrosine kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA

NCBI chr13:28,300,346...28,495,128
Ensembl chr13:28,300,346...28,495,145

G

fms related receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA

NCBI chr 5:180,601,506...180,650,298
Ensembl chr 5:180,601,506...180,649,624

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA

NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978

G

fibromodulin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA

NCBI chr 1:203,340,628...203,351,122
Ensembl chr 1:203,340,628...203,351,758

G

fibronectin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA

NCBI chr 2:215,360,865...215,436,068
Ensembl chr 2:215,360,440...215,436,073

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
Dextran Sulfate results in increased expression of FOS mRNA

PMID:18687398 PMID:35093514

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,283,190

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Dextran Sulfate results in increased expression of FOSL1 protein

NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573

G

forkhead box A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA

NCBI chr20:22,580,998...22,585,490
Ensembl chr20:22,580,998...22,585,455

G

forkhead box A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA

NCBI chr19:45,864,326...45,873,797
Ensembl chr19:45,863,989...45,873,797

G

forkhead box O1

increases expression

Dextran Sulfate results in increased expression of FOXO1 mRNA; Dextran Sulfate results in increased expression of FOXO1 protein

NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641

G

forkhead box O3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA

NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774

G

forkhead box O4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA

NCBI chr X:71,095,851...71,103,532
Ensembl chr X:71,095,851...71,103,535

G

forkhead box P3

increases methylation
increases expression
multiple interactions

Dextran Sulfate results in increased methylation of FOXP3 gene
Dextran Sulfate results in increased expression of FOXP3 mRNA
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]
Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene]

PMID:20881082 PMID:21858153 PMID:31807802 PMID:34998820

NCBI chr X:49,250,438...49,264,710
Ensembl chr X:49,250,438...49,264,800

G

fucose-1-phosphate guanylyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA

NCBI chr 1:74,198,242...74,208,702
Ensembl chr 1:74,198,238...74,234,086

G

formyl peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA

NCBI chr19:51,745,172...51,751,878
Ensembl chr19:51,745,172...51,804,115

G

formyl peptide receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA

NCBI chr19:51,761,180...51,770,531
Ensembl chr19:51,752,026...51,770,531

G

formyl peptide receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPR3 mRNA

NCBI chr19:51,795,157...51,826,190
Ensembl chr19:51,795,157...51,826,190

G

FRAT regulator of WNT signaling pathway 2

increases expression

Dextran Sulfate results in increased expression of FRAT2 mRNA

NCBI chr10:97,332,497...97,334,729
Ensembl chr10:97,332,497...97,334,729

G

follicle stimulating hormone subunit beta

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FSHB protein
gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]

NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261

G

follicle stimulating hormone receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA

NCBI chr 2:48,962,157...49,154,515
Ensembl chr 2:48,962,157...49,154,527

G

follistatin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA

NCBI chr 5:53,480,629...53,487,134
Ensembl chr 5:53,480,626...53,487,134

G

follistatin like 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA

NCBI chr19:676,392...683,385
Ensembl chr19:676,392...683,392

G

FUS RNA binding protein

increases expression

Dextran Sulfate results in increased expression of FUS mRNA

NCBI chr16:31,180,110...31,194,871
Ensembl chr16:31,180,138...31,196,963

G

FXYD domain containing ion transport regulator 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA
Dextran Sulfate results in decreased expression of FXYD1 mRNA

PMID:29950665 PMID:35093514

NCBI chr19:35,137,188...35,143,109
Ensembl chr19:35,138,824...35,143,109

G

FXYD domain containing ion transport regulator 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA

NCBI chr19:35,115,823...35,124,324
Ensembl chr19:35,115,823...35,124,324

G

FXYD domain containing ion transport regulator 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA

NCBI chr10:43,371,636...43,376,335
Ensembl chr10:43,371,636...43,376,335

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA

NCBI chr 6:111,660,332...111,873,452
Ensembl chr 6:111,660,332...111,873,452

G

frizzled class receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA

NCBI chr 7:91,264,433...91,271,326
Ensembl chr 7:91,264,433...91,271,326

G

frizzled class receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA

NCBI chr11:86,945,679...86,955,395
Ensembl chr11:86,945,679...86,955,395

G

frizzled class receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA

NCBI chr 2:207,762,598...207,769,906
Ensembl chr 2:207,762,598...207,769,906

G

frizzled class receptor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA

NCBI chr 8:103,298,494...103,332,866
Ensembl chr 8:103,298,433...103,332,866

G

frizzled class receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA

NCBI chr 2:202,033,855...202,038,441
Ensembl chr 2:202,033,855...202,038,441

G

frizzled class receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA

NCBI chr10:35,638,247...35,642,296
Ensembl chr10:35,638,247...35,642,296

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA

NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438

G

gamma-aminobutyric acid type B receptor subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA

NCBI chr 6:29,602,238...29,633,183
Ensembl chr 6:29,555,629...29,633,976

G

gamma-aminobutyric acid type A receptor subunit alpha2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA

NCBI chr 4:46,243,548...46,390,300
Ensembl chr 4:46,243,548...46,475,230

G

gamma-aminobutyric acid type A receptor subunit alpha5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA

NCBI chr15:26,866,719...26,949,208
Ensembl chr15:26,866,911...26,949,208

G

gamma-aminobutyric acid type A receptor subunit beta2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA

NCBI chr 5:161,288,436...161,548,404
Ensembl chr 5:161,288,429...161,549,044

G

gamma-aminobutyric acid type A receptor subunit delta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA

NCBI chr 1:2,019,345...2,030,758
Ensembl chr 1:2,019,329...2,030,758

G

glutamate decarboxylase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA

NCBI chr 2:170,813,210...170,861,151
Ensembl chr 2:170,813,213...170,861,151

G

UDP-galactose-4-epimerase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA

NCBI chr 1:23,795,599...23,800,754
Ensembl chr 1:23,795,599...23,800,781

G

galactokinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA

NCBI chr15:49,155,774...49,367,740
Ensembl chr15:49,155,656...49,367,869

G

galactose mutarotase

increases expression

Dextran Sulfate results in increased expression of GALM mRNA

NCBI chr 2:38,666,114...38,734,765
Ensembl chr 2:38,666,081...38,741,237

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA

NCBI chr 5:154,190,733...154,420,984
Ensembl chr 5:154,190,730...154,420,984

G

polypeptide N-acetylgalactosaminyltransferase 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA

NCBI chr 9:98,807,670...98,850,081
Ensembl chr 9:98,807,670...98,850,081

G

polypeptide N-acetylgalactosaminyltransferase 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA

NCBI chr 3:16,174,680...16,248,224
Ensembl chr 3:16,174,680...16,231,992

G

polypeptide N-acetylgalactosaminyltransferase 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA

NCBI chr14:69,259,631...69,386,337
Ensembl chr14:69,259,277...69,357,033

G

polypeptide N-acetylgalactosaminyltransferase 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA

NCBI chr11:11,270,877...11,622,005
Ensembl chr11:11,270,877...11,622,005

G

polypeptide N-acetylgalactosaminyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA

NCBI chr 1:230,057,789...230,282,122
Ensembl chr 1:230,057,990...230,282,122

G

polypeptide N-acetylgalactosaminyltransferase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA

NCBI chr12:89,519,412...89,524,796
Ensembl chr12:89,519,412...89,524,796

G

polypeptide N-acetylgalactosaminyltransferase 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA

NCBI chr 2:157,257,705...157,318,491
Ensembl chr 2:157,257,705...157,318,491

G

polypeptide N-acetylgalactosaminyltransferase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA

NCBI chr12:51,351,252...51,391,673
Ensembl chr12:51,351,247...51,392,867

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA

NCBI chr 4:173,168,811...173,323,967
Ensembl chr 4:173,168,811...173,323,967

G

polypeptide N-acetylgalactosaminyltransferase like 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA

NCBI chr 4:171,813,404...173,041,559
Ensembl chr 4:171,812,254...173,041,559

G

GAR1 ribonucleoprotein

increases expression

Dextran Sulfate results in increased expression of GAR1 mRNA

NCBI chr 4:109,815,510...109,824,737
Ensembl chr 4:109,815,510...109,824,740

G

growth arrest specific 8

increases expression

Dextran Sulfate results in increased expression of GAS8 mRNA

NCBI chr16:90,019,633...90,044,960
Ensembl chr16:90,019,629...90,044,975

G

gastrin

decreases response to substance
multiple interactions

GAST protein modified form results in decreased susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA

PMID:16618411 PMID:29950665

NCBI chr17:41,712,331...41,715,969
Ensembl chr17:41,712,331...41,715,969

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of GATA2 mRNA

NCBI chr 3:128,479,422...128,493,201
Ensembl chr 3:128,479,427...128,493,201

G

guanylate binding protein family member 6

increases expression
multiple interactions

Dextran Sulfate results in increased expression of GBP9 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GBP9 protein]

NCBI chr 1:89,364,059...89,388,160
Ensembl chr 1:89,364,059...89,388,160

G

glutamate-cysteine ligase catalytic subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA

NCBI chr 6:53,497,341...53,545,101
Ensembl chr 6:53,497,341...53,616,970

G

glutamate-cysteine ligase modifier subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA

NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456

G

glucosaminyl (N-acetyl) transferase 3, mucin type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA

NCBI chr15:59,611,783...59,622,723
Ensembl chr15:59,594,875...59,640,239

G

GDP dissociation inhibitor 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GDI1 protein

NCBI chr X:154,437,154...154,443,467
Ensembl chr X:154,436,913...154,443,467

G

glutamine--fructose-6-phosphate transaminase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA

NCBI chr 2:69,319,780...69,387,227
Ensembl chr 2:69,319,780...69,387,250

G